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Tuberculosis (TB), pneumonia and human immunodeficiency virus (HIV) were the 
three leading causes of natural deaths in South Africa in 2013 and 11.9% of all 
deaths in KwaZulu Natal were attributed to TB. In 2013, there was an estimated 
5.26 million people infected with HIV in South Africa. HIV infected individuals have 
an increased risk of respiratory tract infections including smear negative TB. Lung 
cancer is the most common type of cancer in the world. However, due to 
infrequent updates of the cancer registry in South Africa, current prevalence is 
unknown. Bronchoscopy is a useful tool for the diagnosis of broncho-respiratory 
pathology.  
 
Aims and Objectives 
This study describes the patient profile and outcomes of bronchoscopy in a tertiary 
centre in KwaZulu Natal in 2011. Specific objectives were to describe 
bronchoscopy indications, microbiological, cellular and histological findings and 
prevalence of TB amongst smear negative patients by broncho-alveolar lavage 
(BAL). In addition, the common types of lung cancer diagnosed on biopsy during 





A retrospective review of consecutive bronchoscopies performed by the 
pulmonologist at a tertiary hospital in western KwaZulu Natal, between 1 January 
and 31 December 2011 was performed. A total of 107 patients met the inclusion 
criteria. Data was collected from clinical records, laboratory and radiology 
computerised record systems and entered on an Excel workbook using Microsoft 
Office 2010® software. Data was analysed using Epi-Info Version 3.5.4® and 
Stata/IC 13.0®. The demographic, bronchoscopy and chest CT scan findings were 
summarised with descriptive summary measures and expressed as means ± 
standard deviation (SD) and/or medians with the range and interquartile range for 
quantitative variables. Percentages, frequencies and proportions were used to 
describe categorical variables. 
 
Results 
The median age of patients was 55 ± 14.4 (Interquartile range (IQR) 43 - 63) years 
and 68 (63.6%) patients were male. Twenty-eight (26.2%) patients were HIV 
infected with a median cluster of differentiation 4 count of 254 ±164 (IQR 126 – 
366.5) cells per cubic millimetre. Nine patients were on antiretroviral therapy.   
 
The commonest indications for bronchoscopy were investigation of a lung mass 
(35.8%), non-resolving lower respiratory tract infection (15%) and suspected TB 
(15%). Microbiological findings on BAL samples included gram positive and 
negative bacteria (14%) and fungi (20%). TB microscopy, polymerase chain 
reaction and culture revealed mycobacterium tuberculosis on 22.2% of all BAL 
samples. Two patients with mycobacterium tuberculosis on BAL samples were 
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HIV infected. The prevalence of TB on smear negative patients was 11.1%. 
Cytological analysis of BAL samples detected pathology on eight (13.1%) patients 
and two (3.3%) of these patients had lung cancer. Malignant (52.9%) (squamous 
cell carcinoma and adenocarcinoma) and benign (11.1%) (pneumonia and 
interstitial fibrosis) pathology was found on histology. Squamous cell carcinoma 
(37%) was the commonest lung cancer detected.  
 
Bronchoscopy was helpful in determining broncho-respiratory pathology in 38 
(35.5%) patients. The commonest diagnosis was lower respiratory tract infection in 
7 of 15 (46.7%) patients referred with diffuse pulmonary infiltrates. Bronchoscopy 
also assisted with the diagnosis of lung cancer in 20 of 43 (46.5%) patients 




Bronchoscopy may be a useful tool in diagnosing and decreasing the morbidity 
associated with respiratory illness in South Africa as the diagnostic yield was 
greatest for lower respiratory tract infections. Samples collected during BAL had a 
relatively low diagnostic yield for TB. Prompt referral of smear negative TB 
suspects is recommended to assist with the microbiological diagnosis of TB and 
direct therapy thereof. 
 
Cytological examination of BAL samples was associated with a low yield of lung 
cancer and biopsy samples were more useful for this purpose. SCC was the 
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commonest histological subtype of lung cancer in this cohort. Bronchoscopy was a 
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In 2012, lower respiratory tract infection (LRTI) was the leading cause of death in 
low income countries, accounting for 91 deaths per 100 000 population.(1) In 
South Africa, tuberculosis (TB) and pneumonia were the leading causes of natural 
deaths in 2013, with 11.9% of all deaths in KwaZulu Natal attributed to TB.(2) 
Although TB and pneumonia are potentially curable, the diagnosis remains a 
challenge.(3) Time delays in obtaining and analysing sputa amongst smear 
negative and resistant TB cases may contribute to this high mortality rate.(4) 
 
Bronchoscopy is a useful tool in achieving microbiological diagnoses in LRTI.(5, 6) 
In particular, broncho-alveolar samples collected during bronchoscopy have a 
higher sensitivity in detecting acid fast bacilli (AFB) in smear negative pulmonary 
TB than sputa samples.(7) Although the use of bronchoscopy in the diagnosis of 
smear negative TB has been well described, detection rates have not been 
documented in high burden human immunodeficiency virus (HIV) and TB 
syndemic areas, like KwaZulu Natal.(8, 9) The current use of broncho-alveolar 
lavage (BAL) in a high TB/HIV prevalence area is explored in this study. 
 
Mortality due to chronic diseases has been increasing globally over the past 
decade.(1) One such chronic disease is lung cancer.(1) Lung cancer is the most 
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common cancer diagnosed worldwide,(10) with a projected increase in disease 
burden by 2030.(11) The true burden of disease in South Africa is largely unknown 
due to lack of updates of the national cancer registry.(12)  
 
The risk of developing lung cancer is higher amongst HIV infected individuals than 
the general population.(13) Considering the burden of HIV infection in South 
Africa, determining the prevalence of lung cancer is a vital initial step in 
establishing links between the two chronic diseases. Despite advances in 
radiology, biopsy of a suspicious lung mass remains the only method for diagnosis 
of lung cancer.(14) Bronchoscopy provides a means to obtain bronchial tissue 
samples and therefore is an essential tool in the diagnosis of lung cancer. 
 
The two most common histological subtypes of lung cancer are squamous cell 
carcinoma (SCC) and adenocarcinoma.(15) Adenocarcinoma is the most common 
lung cancer in western countries(15) whilst in the east, histological subtypes differ 
in different regions.(16, 17) This may be due to different ethnicities, cultures and 
social habits in different regions in the world. In South Africa, individual studies 
from Johannesburg and Bloemfontein report SCC as the most common 
histological subtype of lung cancer.(18, 19) In Cape Town, however, lung 
adenocarcinoma is more common than SCC.(20) Regional bronchoscopy studies 
are therefore important to increase knowledge of lung cancer trends in the 
different settings in South Africa. This study describes the most common 




Due to the lack of information with respect to the outcomes of bronchoscopy in 
KwaZulu Natal; a review of bronchoscopy outcomes between 1 January and 31 
December 2011, at a tertiary hospital in Pietermaritzburg was undertaken. This 
hospital serves 4.5 million individuals in western KwaZulu Natal. The objectives of 
this study were to describe bronchoscopy indications, microbiological, cellular and 
histological findings and prevalence of TB amongst smear negative patients by 
BAL. In addition, the common types of lung cancer diagnosed on biopsy during 


















Tuberculosis (TB) and pneumonia were the two leading causes of natural deaths 
in 2010 in South Africa.(2) In KwaZulu Natal, TB accounted for 12% of all 
deaths.(2) The diagnosis of TB was particularly challenging prior to the 
introduction of the GeneXpert® rapid mycobacterium tuberculosis/ rifampicin 
(MTB/RIF) assay in South Africa. Prior to this, there was a significant delay in time 
to diagnosis of TB especially smear negative and drug resistant TB.(4) These 
delays may have directly contributed to mortality as well as community and 
nosocomial transmission of TB.(4) Furthermore, obtaining sputum may be a 
challenge in patients who are unable to expectorate sputum.(21) The use of chest 
radiographs may be associated with under-diagnosis of TB in these patients.(21) 
 
There is a higher sensitivity of acid fast bacilli on BAL samples than sputum 
samples. Broncho-alveolar lavage (BAL) samples analysed for acid fast bacilli 
(AFB) has proven to have a higher sensitivity than sputum samples for 
mycobacterium tuberculosis amongst smear negative patients.(7) Due to the high 
rates of TB in KwaZulu Natal, a review of bronchoscopies was performed to 
determine the outcomes of bronchoscopy in this high respiratory tract infection 




2.1. Introduction to Bronchoscopy 
Bronchoscopy is an essential tool that is widely used for the diagnosis and 
treatment of broncho-pulmonary diseases.(5, 6) The rigid bronchoscope was first 
introduced by Dr Gustav Killian in 1897.(6) This invention was succeeded by the 
first prototype flexible fiber-optic bronchoscope, developed by Machida and 
presented by Shigeto Ikeda in 1966.(6) This was the beginning of the revolution of 
the world of bronchoscopy.(6) Today both rigid and flexible bronchoscopes are 
used depending on the indication for the bronchoscopy.(5) 
 
There are two types of bronchoscopes; namely rigid and flexible.(5) A flexible 
bronchoscope comprises of three bundles of optical fibers, two of which carry light 
to the distal end and one which projects the image from the distal end to the 
eyepiece.(5) There is an instrument or suction channel at the proximal end which 
allows secretions to be suctioned and samples to be obtained.(5) The distal end 
can be manoeuvred within the airway for better visualisation by means of a lever 
at the proximal end of the bronchoscope.(5) Flexible bronchoscopy is usually 
performed under local anaesthetic.(5) 
 
Rigid bronchoscopes are available in different sizes and have a halogen light 
source.(22) Telescopes of 00, 300 and 900 can be placed down the rigid barrel; to 
improve visualisation of the tracheo-bronchial tree.(22) Instruments to assist with 
biopsy and suction devices may also be placed down the barrel.(22)  Rigid 
bronchoscopy is usually performed under general anaesthesia.(5, 22) 
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2.2. The Bronchoscopy Procedure 
Prior to bronchoscopy, patient informed consent must be obtained and the full 
blood count and clotting profile must be checked to ensure that there will be no 
risk of massive haemorrhage during biopsy.(23) Intravenous access is mandatory 
in all patients.(23) An electrocardiograph is only required if the patient has a 
history of cardiac disease.(23) Bronchodilators may be used if the patient has 
bronchoconstriction.(5, 23, 24)  Ideally patients should be “nil per os” for a 
minimum of four hours before bronchoscopy. (5, 23, 24) 
 
Bronchoscopy is usually performed with the patient in the 450 recumbent 
position.(5, 22) Lignocaine is the local anaesthetic agent of choice to ensure 
patient comfort and should be limited to eight milligrams per kilogram (mg/kg) in 
the adult patient.(5, 23) The route of administration of lignocaine is a matter of 
preference.(5) In a survey amongst respiratory physicians in the United Kingdom 
lignocaine spray was preferred over trans-tracheal lignocaine injection and 
nebulised lignocaine, as a local anaesthetic agent.(25) Supplemental oxygen may 
be used to achieve an oxygen saturation of at least 90% prior to the 
commencement of bronchoscopy.(5)  
 
The bronchoscope is introduced via the nose or mouth, into the glottis and 
tracheo-bronchial tree.(5, 22, 24) The bronchial anatomy down to the sub-
segmental level is inspected for the presence of endo-bronchial lesions and 
mucosal abnormalities.(5, 22, 24) Lavage and tissue samples may also be 
obtained during bronchoscopy.(5, 22, 24) Sampling techniques include bronchial 
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washings, BAL, bronchial brushings, endo-bronchial biopsy, trans-bronchial lung 
biopsy, trans-bronchial fine needle aspiration and endo-bronchial ultrasound 
assisted trans-bronchial needle aspiration.(5, 22) 
 
2.3. Sampling Techniques 
2.3.1. Bronchial Washings 
This is a lavage of the bronchus that requires instillation of between five to 30 
millilitres (ml) of saline into the bronchus to clear secretions or mucus in that 
area.(24, 26) This fluid is then aspirated and used for cytological and 
microbiological analysis.(24) The sample may contain normal respiratory flora.(24) 
This process is commonly used with other sampling techniques.(24) 
 
2.3.2. Broncho-alveolar Lavage 
Like bronchial washings, during BAL, saline is instilled into the bronchial tree.(24) 
It is lavaged into two to three different regions to reach a higher representation of 
the entire lung.(24, 27) The bronchoscope is wedged at the level of the third to 
fourth bronchi, and between 20 ml and 180 ml of saline is instilled.(23, 24, 27) This 
is gently aspirated to prevent bronchial collapse.(23, 24) BAL is helpful in the 
diagnosis and aetiology of many conditions including; interstitial lung disease, 
pneumocystis jirovecii pneumonia (PCP) and pulmonary fibrosis.(24) BAL samples 
of immune-compromised patients, should routinely be sent for AFB and TB 
culture.(23)   
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2.3.3. Bronchial Brushings 
When a lesion is identified at bronchoscopy a brush is passed through the 
instrument channel and advanced three centimetres (cm) out of the distal end.(24) 
The brush is then moved back and forth and brushed over the lesion.(23, 24) 
Thereafter, it is retracted into its sheath and pulled back through the channel.(23, 
24) This sample is used for either cytological or microbiological analysis.(24) 
There are several factors that may influence the diagnostic yield of this 
technique.(24) These include repeated brushings as well as using brushes with 
different diameters and types of bristles for different lesions.(24) Bronchial 
brushing increases the diagnostic yield of lung malignancies in particular.(23) 
 
2.3.4. Endo-bronchial Biopsy 
At bronchoscopy when a lesion is identified, a biopsy is performed under direct 
vision.(24) A biopsy forceps is inserted through the operating channel of the 
bronchoscope in a closed position.(23, 24) After the forceps has reached the distal 
end of the bronchoscope, it is opened, anchored onto the lesion and a biopsy is 
taken.(23, 24) The forceps is removed and the tissue obtained is sent for 
histological analysis.(23) This process may be repeated up to five times.(23, 24)   
 
2.3.5. Trans-bronchial Lung Biopsy  
After complete endo-bronchial inspection of all lung segments, the bronchoscope 
is advanced through to the narrowest airway, until it cannot be advanced any 
further.(24) A biopsy forceps is inserted into the channel and advanced past the 
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distal end of the bronchoscope to the lesion at the periphery of the lung.(24) Endo-
bronchial ultrasound or a fluoroscopy unit may be activated to allow visualisation 
of the forceps as it enters the distal segments of the lung.(24) The forceps is 
retracted one centimetre to avoid a biopsy of the pleura whilst the patient 
inspires.(23) When the patient expires, the forceps is opened, advanced and 
closed.(23) The biopsy is performed and the sample is sent for histological 
analysis.(24) This biopsied area is observed for post-biopsy bleeding using the 
bronchoscope.(24) This procedure may be repeated up to six times to increase the 
diagnostic yield.(23, 24)   
 
2.3.6. Trans-bronchial Needle Aspiration  
This sampling technique is used when a lesion in the mediastinum lies adjacent to 
the tracheo-bronchial tree, in the airway wall or lung parenchyma.(24) The 
bronchoscope is used to locate the lesion and a trans-bronchial needle at the end 
of a catheter, is passed through the bronchoscope to the distal end.(22) The 
catheter and needle tip are moved back and forth to shear cells from the 
lesion.(22) The catheter is then removed and smears of cells may be prepared for 
cytological evaluation.(22) There are different techniques that may be employed to 
ensure an adequate sample is obtained.(22) 
 




The addition of endo-bronchial ultrasound to conventional trans-bronchial needle 
aspiration has assisted with minimising complications.(24) This technique is used 
in the evaluation of mediastinal lymphadenopathy, intrapulmonary tumours and 
lung cancer staging.(24) The endo-bronchial ultrasound assists by identifying 
lesions within the airway and enlarged lymph nodes.(24) The bronchoscope is 
then placed in the area of pathology with ultrasound guidance, and the trans-
bronchial needle aspiration is performed in the conventional manner.(24) This is a 
relatively recent tool in aiding diagnostic bronchoscopy and is currently unavailable  
at Greys Hospital but is available at Inkosi Albert Luthuli Central Hospital. 
 
2.4. Complications of Bronchoscopy 
Bronchoscopy is a relatively safe procedure, however, the risk to benefit ratio 
should be individualised for each patient.(24)  Complications described in a 
university hospital in Columbus, where 4 273 consecutive flexible fiberoptic 
bronchoscopies were reviewed,  included respiratory failure (0.2%), vomiting 
(0.1%), pneumothorax (0.16%), laryngospasm (0.6%), pulmonary haemorrhage 
(0.12%) and bronchospasm (0.02%).(28) A larger, multicentre study conducted in 
19 centres in Italy, reviewed complications in 20 980 bronchoscopies done over a 
year.(29) The overall complication rate was 1.08% with a mortality rate of 
0.02%.(29) The most common complications included haemoptysis of greater than 
50 ml (0.26%), haemoptysis under 50 ml (0.19%), hypoxia (0.12%) and 
pneumothorax (0.1%).(29) Complications were mainly associated with trans-




2.5. Indications for Bronchoscopy 
The indications for flexible and rigid bronchoscopies differ. Rigid bronchoscopy is 
performed mainly for therapeutic procedures such as the removal of foreign 
bodies, tumour ablation, insertion of stents and staging of tumours prior to surgical 
resection by thoracic surgeons.(5) 
 
Flexible bronchoscopies are used for investigation and diagnosis of respiratory 
pathology such as haemoptysis, persistent cough, recurrent lower respiratory tract 
infections (LRTI), suspected lung malignancy and interstitial lung disease.(5) 
There are regional differences regarding the most common indications for 
bronchoscopy.(16) In 1989, the American College of Chest Physicians (ACCP) 
conducted a survey in North America which found that suspected lung cancer was 
the most common indication in 96.4% of bronchoscopies.(15) This differs with 
other studies in the Middle East where 35.9% to 51.6% of bronchoscopies were 
requested for suspected respiratory infection.(16, 17, 30)  
 
In a study conducted in Cape Town between 1976 and 1980 on 705 patients,  
suspected malignancy (41%) and TB (31%) were the most common indications for 
bronchoscopy, however, this study was conducted in a pre-human 
immunodeficiency virus (HIV) era.(31) HIV infected patients are more at risk of 
pneumonia and smear negative TB.(3) It is uncertain if this risk of lower respiratory 
tract infection amongst the HIV infected population has altered the indications for 




2.6.1. The Burden of Tuberculosis 
Tuberculosis is an airborne infection caused by mycobacterium tuberculosis.(32) 
The characteristic symptoms of the disease are that of persistent cough or fever of 
two weeks or more, drenching night sweats and unexplained loss of weight.(21, 
32) Other symptoms include chest pain, breathlessness and wheezes.(21) An 
individual is regarded as a TB “suspect” if a cough is present for two or more 
weeks.(21) The absence of a cough, however, does not exclude TB and a high 
index of suspicion must be maintained especially in HIV infected individuals.(21) 
 
According to the 2012 Global TB report, there were an estimated 8.7 million 
incident cases of TB in the world with 0.4 to 0.6 million cases in South Africa.(33) 
South Africa has the highest incidence (1 180 per 100 000 population) and 
prevalence (1 250 per 100 000 population) of TB in the world.(33) In addition, 
South Africa also has the leading HIV prevalence amongst patients with TB, in the 
world.(33)  
 
Globally, there were 1.4 million reported deaths from TB in 2011 (990 000 HIV 
uninfected and 430 000 HIV infected individuals).(33) Over 95% of TB deaths 
occurred in low-middle income countries.(33) In South Africa the leading cause of 
natural deaths from 2011 to 2013 was TB (10.7% in 2011, 9.9% in 2012 and 8.8% 




The burden of TB in South Africa is exacerbated by its drug resistant strains.(34) 
Multi-drug resistant TB (MDR TB) is defined as mycobacterium tuberculosis that is 
resistant, in vitro, to both rifampicin and isoniazid.(21, 35) Extreme drug resistant 
TB (XDR TB) is mycobacterium tuberculosis that is resistant, in vitro, to rifampicin, 
isoniazid, any one of the fluoro-quinolones and any one of the second line 
injectable drugs (capreomycin, kanamycin or amikacin).(21, 35) Between 2004 
and 2010, there were 45 196 laboratory confirmed cases of MDR TB and 3 128 
laboratory confirmed cases of XDR TB in South Africa.(34) KwaZulu Natal had the 
highest number of both MDR TB (11 393 confirmed cases) and XDR TB (1 499 
confirmed cases) diagnoses.(34)  
 
2.6.2. Diagnosis of Pulmonary Tuberculosis 
The screening tools for the diagnosis of TB in South Africa has recently been 
revised. The South African 2009 TB guidelines suggested that TB diagnosis be 
made on the collection of two sputum specimens on consecutive days for TB 
smear microscopy.(36) The first sample needed to be a spot sputum sample, 
whilst the second sample needed to be an early morning specimen.(36) If the 
patient was HIV infected then a third sample would be required for TB smear and 
culture.(36) The aim for sputum turnaround time was 48 hours.(36) This guideline 
has been revised due to the advent of GeneXpert ®.  
 
Current TB guidelines in South Africa recommend that TB is diagnosed by 
GeneXpert® performed on one sputum sample.(21) If this is positive and the TB is 
sensitive to rifampicin, TB treatment is commenced, microscopy is performed and 
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the patient is treated according to the results.(21) If the GeneXpert® is positive 
and the TB is resistant to rifampicin then treatment for MDR TB is commenced, 
culture and drug susceptibility testing are performed and the patient is further 
managed according to the results.(21) If GeneXpert® is negative and the patient is 
HIV infected then culture and drug susceptibility testing are performed and the 
patient is further investigated for TB with a chest radiograph whilst commenced on 
empiric antibiotics.(21) If the GeneXpert® is negative and the patient is HIV 
uninfected then empiric antibiotics are commenced.(21) (Appendix 2) 
 
a. GeneXpert® and pulmonary Tuberculosis 
The GeneXpert® assay uses deoxyribonucleic acid (DNA) sequences amplified in 
a real time polymerase chain reaction (PCR) assay to detect mycobacterium 
tuberculosis and determine sensitivity of the strain to rifampicin.(37) In 95% of 
rifampicin resistance strains, there is a mutation located within the 81bp core 
region of the ribonucleic acid polymerase beta subunit gene.(37) The core region 
is flanked by mycobacterium tuberculosis complex specific DNA sequences.(37) 
This allows the simultaneous diagnosis of TB and rifampicin resistance by 
targeting one amplicon generated with PCR.(37) The assay is able to detect 131 
colony forming units (cfu) per ml of sputum, which is much higher than that of 
microscopy and culture.(37) The test can be performed in two hours which has 
improved time to detection of TB infection and rifampicin resistance.(37) 
GeneXpert® can be performed on gastric lavage samples for the diagnosis of TB, 




In a multicentre trial, in Durban and Cape Town, the sensitivity of GeneXpert® for 
pulmonary TB, amongst HIV infected individuals with culture positive TB was 
93.9% as compared with 98.4% in HIV uninfected individuals with culture positive 
TB (P = 0.02).(4) In the same study, the sensitivity and specificity of GeneXpert® 
on sputum smear negative samples was 86% and 90% respectively(4). When the 
sensitivities and specificities for rifampicin resistance in Cape Town were 
assessed it was 93% (15 of 16 patients) and 100% (126 of 126 patients) 
respectively, whereas in Durban both sensitivity (3 of 3 patients) and specificity (38 
of 38 patients) was 100%.(4) A subsequent meta-analysis of 15 studies using 
GeneXpert® on sputa for TB detection found a pooled sensitivity of 90.4% and 
pooled specificity of 98.4%.(37) The pooled sensitivities of smear negative and 
smear positive disease in the same cohorts were 75.0% and 98.7% 
respectively.(37) 
 
b. Sputum for acid fast bacilli (smear positive Tuberculosis) 
Acid fast bacilli examination on sputa is widely performed in South Africa in 
regions without access to GeneXpert®, in all cases where GeneXpert® is positive 
and for monitoring of response to TB treatment.(21) TB “suspects” are required to 
produce two sputa samples, the first is a “spot” or immediate sample and the 
second is an early morning sample.(21) These are analysed to detect AFB using 
either Ziehl Neelsen (Carbol Fuchsin) staining or fluorescent auramine 
staining.(21) For the detection of pulmonary TB, these stains may be performed on 
sputa or BAL samples.(21) The sensitivity and specificity for AFB on sputa in HIV 
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infected individuals is 53.3% (95%CI 38-68%) and 89.5% (95%CI 79.7-95%) 
respectively.(38) 
 
Acid fast bacilli detection on induced sputum may be considered in patients unable 
to produce sputum.(39) In a prospective study in Bangladesh, conducted on 52 
smear negative patients, suspected of having TB, the sensitivity of AFB-smears in 
samples from induced sputum and BAL were 74% and 58% respectively.(39) 
Fishers Exact test performed on induced sputum and BAL groups showed they 
were in agreement in 90% cases (p=0.0001).(39) 
 
Another study conducted in Brasil between 1996 and 1998, demonstrated no 
significant differences in the yields of AFB smears or cultures whether obtained via 
sputum induction or BAL.(40) In the study, among 207 HIV-seronegative patients, 
the AFB smear and mycobacterial culture results from specimens obtained by 
sputum induction and BAL were in agreement in 97% (202 of 207) (kappa test = 
0.92) and 90% (186 of 207) (kappa test =0.78), respectively.(40) 
 
c. Tuberculosis culture 
A more sensitive test to detect TB is culture of mycobacterium tuberculosis.(21) 
However; this method may take between four to six weeks to provide a result and 
is prone to contamination.(21) Samples that may be sent for TB culture include 
sputa and BAL samples.(21) Cultures should routinely be requested for all TB 
“suspects” who have a positive GeneXpert® and rifampicin resistance, a negative 
33 
 
GeneXpert® and HIV infection, two negative sputa smears for AFB and HIV 
infection, TB “suspects” who were previously treated for TB and those with MDR 
TB or XDR TB contacts.(21) 
 
A liquid culture medium is usually used in conjunction with a solid medium as a 
“backup” system.(21, 41, 42) The solid medium uses coagulated egg (e.g. 
Lowenstein-Jensen) or agar (Middlebrook 7H10) as a base.(21, 42) For the liquid 
medium technique, a semi-automated radiometric system with radiation 
technology (e.g. BACTEC 460) may be used.(21) Alternatively, an automated non 
radiometric system, using fluorometric technology (e.g. mycobacteria growth 
indicator tube) may be used.(21) 
 
d. Drug susceptibility testing for pulmonary Tuberculosis 
This test determines if the mycobacterium tuberculosis organism is sensitive or 
resistant to individual drugs namely; rifampicin, isoniazid, pyrazinamide, 
ethambutol, moxifloxacin, ofloxacin, streptomycin, kanamycin, capreomycin, 
amikacin and ethionamide.(21) The test is indicated in patients who have taken TB 
treatment previously and high risk TB “suspects” with MDR TB and XDR TB 
contacts.(21) This test may be done by direct or indirect means.(21) Direct tests 
are performed on samples that are rich in bacilli, whilst for indirect approaches, 
cultures have to be grown and tested in the exponential phase of growth.(21) The 




e. Chest radiographs and Tuberculosis 
Although radiographs are the quickest and easiest way to determine and confirm 
the presence of lung pathology, they cannot make a microbiological diagnosis of 
TB.(21) Chest radiographs often lead to under or over-diagnosis of TB.(21) They 
are indicated in patients who cannot produce sputum and HIV infected patients 
with a negative GeneXpert®.(21) Chest radiograph findings that may be 
compatible with TB include cavities, ill-defined infiltrates, multiple nodular infiltrates 
and infiltrates with mediastinal enlargement.(43)  
 
2.6.3. The Challenge of Tuberculosis Diagnosis in HIV Infected Individuals 
The rates of TB detection are much lower in HIV infected individuals.(37) A meta-
analysis of seven studies compared the sensitivity of sputum microscopy and 
GeneXpert®, with culture as the gold standard, in HIV infected patients.(37) The 
median sensitivity of smear microscopy was 52.8%, whilst that of GeneXpert® was 
84.0%.(37) A median increment of 30% was noted using GeneXpert® in all seven 
studies.(37) The overall sensitivity of GeneXpert® was between 58.3% and 
91.7%.(37) When the sensitivity of sputum microscopy and GeneXpert® were 
compared at an antiretroviral clinic in South Africa, the overall sensitivity of the 
GeneXpert® for culture positive TB was 73.3% (specificity 99.2%) compared to 
28% (specificity 100%) using smear microscopy.(44) Similarly in an HIV infected 
cohort in Tanzania, the specificity of GeneXpert® for culture positive TB was 98% 




Other studies from developing countries, Cape Town, South Africa; Kampala, 
Uganda; Jharkhand, India and suggest that in HIV infected patients with smear 
negative TB, analysis of BAL samples offer better detection rates.(7, 8, 23, 46) In 
a cohort of HIV infected patients with smear negative TB and sputa culture as the 
gold standard test, BAL microscopy had a sensitivity of between 10% and 30% 
whilst BAL culture had a sensitivity of between 52% and 95%.(23) When PCR was 
performed on these BAL samples, the resultant sensitivity was 85.7% and 
specificity was 90.9%.(23) Various other studies have also indicated that the use 
of bronchoscopy with BAL reduces the time to diagnosis and increases the 
sensitivity of pulmonary TB diagnosis in HIV infected smear negative patients.(8, 
9) 
 
A study conducted  on 496 patients, between 2007 and 2010 in two primary care 
clinics in Cape Town, South Africa demonstrated that amongst smear negative 
patients, GeneXpert® was able to detect 58% more TB on BAL samples 
compared to microscopy smears.(47) GeneXpert® on BAL samples proved to be a 
rapid diagnostic tool and reduced rates of empirical TB treatment.(47) The use of 
bronchoscopy and GeneXpert® as a diagnostic tool for TB may therefore improve 
the case detection rates in South Africa.(47) 
 
2.7. Lung Cancer 
2.7.1. Introduction and Burden of Disease 
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Lung cancer is the most common type of cancer in the world.(48) In 2012, there 
were an estimated 1.8 million new cases diagnosed globally.(48) At least 58% of 
these new diagnoses occurred in less developed countries.(48) Globally the 
highest incidence of lung cancer for men occurred in central Europe, eastern 
Europe and eastern Asia, whilst for women it occurred in North America, northern 
Europe and eastern Asia.(48) 
 
In 2000, lung cancer was the leading cause of fatal cancers in South Africa with 
the highest rates amongst males and females in the Western Cape.(49) The South 
African  national cancer registry was last updated in 2006.(12) At the time, lung 
cancer was the fifth most common cancer diagnosed in males with an age 
standardised incidence rate of 8.75 per 100 000 world standard population.(12) 
Lung cancer amongst females was 3.52 per 100 000 age standardised incidence 
rate per world standard population.(12) The cancer registry has not been updated 
since 2006 and lung cancer trends in South Africa have not been evaluated in the 
past eight years.(12) As a result, all cancers now need to be notified on a cancer 
registration form and submitted to the National Cancer Register. 
 
A study done in 24 villages in Mpumalanga/Bushbuckridge Local Municipality, 
South Africa, in 2011, found that cancer was amongst the top five causes of death 
in patients over 15 years (14 of 286 patients in the age group 15-49 years, 7 of 
108 patients in the age group 50-64 years and 21 of 162 patients in the age group 




A study investigating cancer projections to 2030, indicates that lung cancer is likely 
to remain a global epidemic.(11) The study extrapolated data from the global 
cancer report and analysed the human development index, life expectancy, 
education, gross domestic product per year and global cancer trends from 1988 to 
2002.(11) In very high human development index areas (North America, Australia, 
New Zealand, Britain and western Europe) and high human development index 
areas (South America, western Europe, northern Europe and southern Europe), 
female breast, lung, colorectal and prostate cancer will account for nearly half of 
the overall cancer burden (1 031 million persons).(11) In medium human 
development index  areas (Asia, South Africa and other African countries) lung 
and female breast cancers will be the most common cancers (773 000 persons 
and 500 000 persons respectively).(11, 51) 
 
Lung cancer is divided into 2 histological subtypes namely; non-small cell 
carcinoma (adenocarcinoma, squamous cell carcinoma (SCC) and large cell 
carcinoma) and small cell carcinoma (oat cell).(52, 53) Peripheral lung cancers 
tend to be adenocarcinoma, whilst central cancers are more likely to be SCC(54). 
  
2.7.2. Risk Factors for Lung Cancer 
a. Modifiable risk factors 
i. Tobacco smoking and lung cancer 
Tobacco smoking is a well-recognised risk factor for lung cancer.(55) Tobacco 
contains at least 20 substances that are carcinogenic.(56) In addition to the 
38 
 
carcinogens in tobacco, lung cancer risk depends on the duration of smoking, 
frequency of smoking, age of smoking initiation and the type of tobacco used.(56)  
 
An autopsy study, conducted from 1998 to 2004 in 5 340 South Africans adults, 
directly linked 58% of lung cancer deaths to smoking.(55) Another study 
describing smoking related mortality in South Africans aged 35 to 74 years, found 
that smoking prevalence was highest in the Coloured population.(57) Lung cancer 
mortality, however, was highest in African, male smokers and White, female 
smokers.(57) The reasons for this were unclear.(57)  
 
In an attempt to regulate tobacco product use in South Africa, the Tobacco 
Products Control Act (amended as the Tobacco Products Control Amendment Act, 
Act Number 63 of 2008) was introduced.(58) Under this act, regulations were 
introduced regarding the production, marketing, advertising, selling and smoking of 
tobacco in public places.(58) It is unclear how these laws may have influenced 
trends in lung cancer in South Africa.  
 
There are many unanswered questions about the recently popular electronic 
cigarettes.(59) The impact of electronic cigarettes on lung cancer trends are 
undetermined; however, they are still classified as tobacco products.(59) The risk 
of nicotine vapour and other harmful substances in these electronic cigarettes is 




ii. Occupational carcinogens and lung cancer 
Occupational exposure to carcinogens is a major contributing factor to the 
development of lung cancer.(56) Common carcinogens include arsenic, asbestos, 
beryllium, cadmium, chromium, diesel, nickel and silica.(56, 60) This makes 
people working at gold mines, refineries, construction industries, shipbuilding and 
motor-vehicle industries, painters and with wood at risk.(56)  
 
The prevalence of lung cancer for every occupation at risk is unavailable in South 
Africa; however, individual studies in mine workers have been performed. A South 
African study that focused on lung cancer in amphibole miners who used two 
types of asbestos rocks; amosite and crocidolite, found that crocidolite was more 
carcinogenic.(61) In the cohort of 7 317 patients, 1 225 (17%) patients died with 56 
deaths attributable to lung cancer.(61) 
 
The link between silica dust, silicosis and lung cancer is well described, however, 
it is unclear whether silica dust exposure in the absence of silicosis increases the 
risk of lung cancer.(62, 63) Confounding factors like smoking make it difficult to 
assess the true exposure-response relationship between lung cancer and 
silica.(62, 63)   
 
iii. Environmental pollution and lung cancer 
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Environmental pollution, in the form of motor vehicle exhaust fumes, heating 
systems, wood fired ovens, cooking with seed oils, industrial emissions and radon 
gas, are risk factors for lung cancer.(56) An estimated 20% of South Africans use 
coal or biomass fuels for cooking or heating.(64) This exposure was estimated to 
have caused 2 489 deaths in South Africans in 2000.(64) It is unclear as to how 
many of these affected individuals developed lung cancer.(64)  
 
Smoking may pose a synergistic effect with environmental pollution in the 
development of lung cancer.(56) Radon gas in particular has shown to account for 
between 10% and 20% of all lung cancers.(56) There have been further 
associations between the exposure to radon gas and mutations in p53 genes 
predisposing exposed individuals to lung cancer.(56) 
 
b. Non modifiable risk factors 
i. Gender and lung cancer 
A review of lung cancer trends in South Africa between 1995 and 2006 
demonstrates that the mortality rate in females increased at an annual rate of 0.19 
per 100 000 persons (p= 0.043).(65) The reason for this finding was uncertain and 
in the absence of South African data post 2006, it is unknown if the mortality rate 




Although, overall, the rates of lung cancer are higher in men than women, women 
are more susceptible to disease.(56, 66) The pathogenesis for this is incompletely 
understood but hormonal factors are postulated.(56, 66) Oestrogens may act as 
lung tumour promoters and have been associated with lung adenocarcinoma in 
particular.(66) 
 
ii. Age and lung cancer 
There are more incident cases of lung cancer reported after the age of 65 
years.(56) This is in keeping with the time that it takes for the effect of smoking on 
the lung to be evident.(56) Patients who are younger than 50 years of age at the 
time of the diagnosis tend to have a better prognosis.(67) 
 
iii. Ethnic differences and lung cancer 
Ethnic differences have been observed with higher mortality rates in African 
Americans and New Zealand Māoris.(56) Chinese women also have a higher 
incidence of lung cancer, however, it is currently uncertain if this is due to a 
genetic predisposition or due to widespread use of wood fired ovens and cooking 
with seed oil.(56) 
 
The last national cancer registry does not categorise lung cancer prevalence by 
race.(12) A South African study evaluating smoking related mortality in different 
races demonstrated that Coloured males had the highest relative risk of 
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developing lung cancer.(57) The Coloured male group was followed by a group of 
Other races, Whites and lastly Blacks.(57) The relative risk of lung cancer 
amongst female smokers was highest in the group of Other races followed by 
White, African and Coloured smokers.(57) Confounding factors such as; smoking 
in each ethnic group, may have contributed to the difference in results in males 
and females.(57)    
  
iv. Lung disease and lung cancer 
Lung disease such as; sarcoidosis, chronic obstructive pulmonary disease 
(COPD) and silicosis, may cause inflammation of the lung which predisposes to 
lung cancer.(56) There is a strong link between smoking and the development of 
COPD.(56) This poses a higher risk of lung cancer with 8.8% of cases leading to 
lung cancer within 10 years.(56)    
 
There is conflicting evidence regarding an association between TB and lung 
cancer.(68) Experimental evidence suggests that mycobacterium tuberculosis is 
capable of DNA damage which has been associated with inflammation related 
carcinogenesis.(68) Mycobacterium tuberculosis may also enhance bcl-2 
oncogene synthesis which increases anti-apoptotic activity.(68) It is hypothesised 
that the combination of DNA damage, apoptosis inhibition and chronic 




A review of 37 case control and four cohort studies (published between January 
1966 and January 2009) on MEDLINE, PubMed, EMBASE and China National 
Knowledge infrastructure databases show an increased lung cancer risk 
associated with TB.(69) This association was not related to the confounding 
effects of tobacco smoking or the timing of TB diagnosis.(69) The association was 
related to adenocarcinoma only (relative risk = 1.6; 95%CI 1.2-2.1).(69)  
 
Another review of the PubMed database up to June 2008 found that the co-
existence of TB and lung cancer was merely a co-incidence.(68) Since the studies 
used in this review were retrospective and prone to recall bias, the association 
between TB and lung cancer remains an area of potential research.(68)  
 
The risk of developing lung cancer is higher in HIV infected individuals than the 
general population.(13) Lung adenocarcinoma is the most frequently diagnosed 
lung cancer in HIV infected individuals.(13) Confounding factors such as tobacco 
smoking and chronic immunosuppression limit the conclusions in terms of an 
association between lung cancer and HIV.(13) It is unclear if HIV has oncogenic 
potential.(13) In vitro studies suggest that HIV produces a trans-activator of 
transcription gene, which can increase the expression of proto-oncogenes and 
down regulate tumour suppressor gene p53, in lung adenocarcinoma lines.(13) 
This hypothesis is yet to be proven.(13) HIV infected individuals may also have an 
increased susceptibility to carcinogens present in tobacco smoke, however, the 
evidence for this is also conflicting.(13) There is no clear relationship between the 
degree of immunosuppression and lung cancer risk.(13) 
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In the pre-antiretroviral therapy (ART) era in the United States of America, lung 
cancer was the most commonly diagnosed non-acquired immunodeficiency 
syndrome defining malignancy.(13) A study from South Africa in 2000, reported no 
increase in prevalence of lung cancer amongst HIV infected patients.(70) More 
recent South African studies evaluating lung cancer prevalence in HIV infected 
patients are unavailable.   
 
v. Family history and lung cancer 
There is a definite association between the risk of lung cancer and a family history 
of lung cancer in a first degree relative.(71) This may be attributed to 
environmental or genetic factors.(71) Studies have observed a significant 
association between the presence of a family history of lung cancer and the 
histological subtype of the predisposed patients.(71) SCC incidence tends to be 
higher when there is a positive family history.(71) 
 
vi. Molecular genetics and lung cancer 
Chromosomal aberrations and fractional allele loss are higher in smokers than 
non-smokers.(72) Point aberrations occur in different areas in the two groups.(72) 
The 6q region of the chromosome has been identified as a susceptible locus for 
lung cancer in family linkage studies.(72) Several oncogenes have been 
associated with adenocarcinoma.(72) These oncogenes cause point mutations but 




Mutations cause an overexpression of epidermal growth factor receptor (EGFR) 
tyrosine kinase which accelerates tumour cell proliferation.(72) There is an inverse 
relationship between EGFR mutations and tobacco smoke exposure, such that 
these mutations are not detected in patients with lung cancer and a 75 pack year 
smoking history.(72) The Kirsten rat sarcoma (KRAS) viral oncogene homolog is 
another member of the EGRF group but is found mainly in patients who smoked 
and have adenocarcinoma.(72) KRAS mutations are usually glutamine-to-tyrosine 
transversion.(72) Unlike KRAS, v-erb-b2 avian erythroblastic leukaemia viral 
oncogene homolog 2 (ERBB2) oncogenes occur with adenocarcinoma in patients 
who have never smoked.(72) Furthermore, ERBB2 mutations  are not detected in 
tumours containing either EGRF or KRAS mutations.(72)  
 
Mutations of p53, a tumour suppressor gene, has shown to be present in between 
40% and 60% of non-small cell lung carcinoma.(72) Such mutations are more 
common in smokers than non-smokers.(72) Tobacco associated lung cancer is 
characterised by transversion mutations (substitution of a purine for a 
pyrimidine).(72) Lung cancer in people who have never smoked is associated with 
transition mutations (purine for purine or pyrimidine for pyrimidine).(72) 
 
Biomarkers like serum amyloid A have been used to detect lung cancer but do not 
further indicate the histological subtype of the cancer.(73) Other biomarkers 
namely; haptoglobin alpha, serum amyloid protein, apolipoprotein A1 and as 
mentioned EGFR detect adenocarcinoma, whilst dihydrodiol dehydrogenase non-
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specifically suggests non-small cell lung cancer.(73) EGRF mutations are almost 
exclusively found in adenocarcinoma, but may be present in SCC also.(73) 
 
2.7.3. Diagnosis of Lung Cancer 
a. Chest radiograph 
The indications for a chest radiograph include symptoms or signs of lung cancer 
namely; haemoptysis, cough, shoulder or chest pain, dyspnoea, unintentional 
weight loss, hoarseness of voice, finger clubbing, cervical or supraclavicular 
lymphadenopathy or features suggestive of metastases from a lung cancer, which 
persists beyond three weeks.(52) The detection of pulmonary nodules on 
traditional chest radiograph alone is challenging, but the use of grey-scale 
inversion on the radiograph may improve nodule detection and eliminate false 
positive nodule findings.(74) 
 
b. Sputum cytology 
According to the National Institute for Health and Clinical Excellence (NICE) and 
ACCP guidelines, cytological analysis of sputum is rarely diagnostic.(52, 75) The 
recommendation is that it should only be performed on patients with central lung 
masses or when patients are unwilling to undergo bronchoscopy or other invasive 
tests.(76) This recommendation has been supported by studies that demonstrate 
the sensitivity of sputum cytology to be as low as 0.2%.(77) Factors affecting the 
yield of cytology vary depending on the site of the lung mass, the number of 
samples analysed and the presence or absence of co-existing respiratory 
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infection.(76) Since a negative finding does not exclude lung cancer, patients may 
need further investigations.(76) This is therefore, not a cost effective screening 
tool.(76)  
 
c. Chest computed tomography scan for lung cancer screening and 
management of pulmonary nodules 
Routine screening of smokers and high risk individuals for lung cancer remains 
controversial. The National Lung Screening Trial conducted in the United States of 
America, showed that screening for lung cancer with low dose chest computed 
tomography (CT) scan rather than chest radiograph reduced mortality from lung 
cancer.(78) Low dose chest CT scan, as a lung cancer screening test, proved 
superior with a sensitivity of 93.8% compared to 73.5% on chest radiography.(78) 
The specificity of low dose chest CT scan was, however, less than chest 
radiography (73.4% compared to 91.3%).(78) These findings have been similar to 
other large studies of low dose chest CT screening for lung cancer namely; the 
International Early Lung Cancer Action Program(79) and a Dutch Belgian lung 
cancer screening trial.(78-80)   
 
Screening by low dose chest CT scan has raised several concerns such as the 
cost effectiveness of this tool, the large number of false positives on chest CT 
scan (98% in the National Lung Screening Trial), the radiation exposure delivered 
by repeat scans and the management of pulmonary nodules detected on the 
scans.(81) Further investigation of the National Lung Screening Trial demonstrates 
that over-diagnosis of lung cancer is also a major concern in low dose chest CT 
48 
 
screening.(82) In this trial, the probability of over-diagnosis of any lung cancer 
detected by screening was 22.5% (95%CI 9.7-34.3%) whilst the probability of 
over-diagnosis of broncho-alveolar carcinoma was 78.9% (95%CI 62.2-
93.5%).(82) 
 
Current recommendations by the NICE guidelines is that routine screening of 
smokers is not yet advocated.(52) Annual low dose chest CT screening is, 
however, recommended in the ACCP guidelines to patients between 55 and 74 
years old with a 30 pack year smoking history and greater.(75)  
 
When nodules are detected on a chest CT scan, they are classified as benign, 
malignant or indeterminate.(81) Features suggesting benign nodules include fatty 
plaques, calcification within the nodule or polygonal shaped nodules.(81) These 
features are in keeping with hamarto-chondroma, post-infectious granulomas and 
lymph nodes.(81)  
 
After benign disease is excluded, features of malignant disease are assessed. 
Predictors of malignant disease include; solid or semi-solid nodules measuring 
more than 10 mm, nodule/s with speckled outlines and with air bronchograms or 
pleural retraction, nodule/s in the upper lobe and a low nodule count (less than or 




If the nature of the nodule does not meet the criteria for benign or malignant 
disease, it is deemed indeterminate.(81) Such nodules should be followed up by 
repeat chest CT scan in two years.(81) It is generally accepted that solid nodules 
that remain unchanged in size for two years are benign.(81) Any change in size of 
25% or more is deemed significant.(81) 
  
d. Bronchoscopy and lung cancer 
Bronchoscopy is beneficial as it provides a means for tissue diagnosis which 
determines the histological subtype of the lung cancer.(14) When bronchoscopy 
was compared to chest CT scan for the detection of endo-bronchial tumours, it 
was found to be superior with bronchoscopy detecting 37% more malignancies 
than chest CT scan.(85)  
 
Chest CT scan is helpful prior to the bronchoscopy as it directs the bronchoscopist 
toward the mass and allows a biopsy method to be chosen.(24) Bronchoscopy has 
a high positive predictive value of between 70% and 90% for obtaining a tissue 
diagnosis of central lung lesions (less than four cm from the lobar bronchus) with 
poorly defined margins.(14) Peripheral lesions towards the outer third of the lung, 
are associated with lower yields of cancer detection during bronchoscopy(86) and 
a chest CT or ultrasound guided trans-thoracic biopsy may be considered 
instead.(24) Other studies, however, suggest that the sensitivity for detecting 
small, peripheral lung cancers on bronchoscopy varies from 38% to 86% 
depending on the size of the mass.(87) 
50 
 
Detection of lung cancer using biopsy during bronchoscopy ranges between 57% 
and 94%.(16, 30, 88-90) Rates of detection of lung cancer may be improved by 
direct visualisation of the tumour and multiple biopsies of the same lesion.(91) 
Rapid on site evaluation of trans-bronchial needle aspirates obtained using 
bronchoscopy maybe helpful in ensuring that all samples obtained are suitable to 
improve sensitivity for malignancy detection.(91) However, this is time consuming 
for the cyto-pathologist and may not be feasible in resource limited settings.(91)  
 
The use of advanced bronchoscopy, namely auto-fluorescent bronchoscopy, 
endo-bronchial ultrasound and virtual bronchoscopic navigation, further improve 
the diagnostic yield of the biopsy.(24) Navigational bronchoscopy has facilitated 
easier diagnosis of small, peripheral lesions.(87) Electromagnetic navigation may 
increase bronchoscopy diagnostic yields of lung cancer from 69% to 74%.(87)  
When electromagnetic navigation assisted bronchoscopy is combined with endo-
bronchial ultrasound, the sensitivity is greater than when either modality is used 
alone.(87) 
 
Virtual bronchoscopic navigation generates virtual images of the bronchial path to 
the peripheral lesion.(87) As the virtual images are similar to the bronchoscopy 
images, the bronchoscope may be advanced to the lesion using the virtual images 
to navigate the bronchial tree.(87) The diagnostic yield for small, peripheral lung 
lesions is further increased when virtual bronchoscopic navigation is combined 





Although the use of bronchoscopy in the diagnosis of TB and lung cancer is well 
defined, little is known about the outcomes of bronchoscopy in South Africa. This 
is important as one of the main indications for bronchoscopy is to diagnose 
LRTI(31) which is also the leading cause of mortality in South Africa.(2) Whilst 
bronchoscopy is not the panacea to the diagnosis of TB and LRTI infections, this 
technology offers better detection rates amongst smear negative TB suspects.(23) 
Such a tool in KwaZulu Natal, where TB accounts for 12% of all deaths, is 
meaningful when appropriately applied.(2) Furthermore, since smear negative TB 
is more common amongst HIV infected individuals, and KwaZulu Natal has the 
highest rates of TB and HIV co-infection in South Africa,(33) this study evaluated 
the outcomes of bronchoscopy as well as the prevalence of smear negative TB 
detected by bronchoscopy at this site in western KwaZulu Natal.  
 
The other main indication for bronchoscopy is the diagnosis of lung cancer.(31) 
Lung cancer is emerging as the most common cancer associated with mortality 
worldwide, and especially in high income countries.(1) The burden of lung cancer 
in South Africa is unknown due to infrequent updates of lung cancer registers. In 
KwaZulu Natal, the prevalence of lung cancer is not known. This study 
investigated the prevalence of lung cancer and the frequencies of histological 








3.1. Aim of the Study 
To describe the outcomes of bronchoscopies undertaken at a tertiary hospital in 
KwaZulu Natal in 2011 
 
3.2. Specific Objectives 
3.2.1. To list the indications for bronchoscopy at Greys Hospital 
3.2.2. To describe the microbiological, cellular and histological findings at 
bronchoscopy 
3.2.3. To determine the prevalence of tuberculosis diagnosed on broncho-alveolar 
lavage amongst smear negative patients 












4.1. Study Design  
This is a hospital based, retrospective study, of consecutive patients who had a 
bronchoscopy at Greys Hospital, department of Internal Medicine, between 1 
January and 31 December 2011.  
 
4.2. Study Population 
Greys Hospital is a tertiary care hospital located in Pietermaritzburg and provides 
services to 4.5 million individuals in western KwaZulu Natal.(92) The study 
population included patients older than 18 years, referred to the pulmonologist at 
Greys Hospital, for further investigation and management of lung diseases. The 
study participants were both in and out-patients. 
 
4.3. Inclusion Criteria 
All patients for whom a fiber-optic bronchoscopy was performed, between 1 
January and 31 December 2011. 
 
4.4. Exclusion Criteria 
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4.4.1. All patients who did not have a bronchoscopy due to contra-indications  
4.4.2. Failed bronchoscopy  
4.4.3. All patients under the age of 18 years 
4.4.4. All bronchoscopies not conducted in the bronchoscopy suite at Greys 
Hospital 
4.4.5. Repeat bronchoscopies 
 
4.5. Sample Size 
This was a convenience sample. A total of 129 bronchoscopy procedures were 
requested between 1 January 2011 and 31 December 2011. Of this, 22 patients 
were excluded due to failure to meet the inclusion criteria. Reasons for exclusion 
included: 12 bronchoscopies were not undertaken in the bronchoscopy suite, two 
patients were underage and two procedures were cancelled for unclear reasons. A 
total of six bronchoscopies were repeated hence these were included only once. 
The reasons for repeat biopsy requests were a high international normalised ratio 
(INR) result (one case, INR=1.92), an absent INR result (one case), technical 
difficulty at first bronchoscopy attempt (three cases) and a repeat bronchial lavage 
for a non-resolving lower respiratory tract infection (LRTI) where no microbiology 
result was obtained (one case).  A total of 107 patients met the inclusion criteria of 
the study and were analysed. 
 
4.6. Data Collection Methods and Tools 
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A review of all bronchoscopies performed on adult patients in the bronchoscopy 
suite of Greys Hospital between 1 January and 31 December 2011 was 
conducted. All the bronchoscopies were performed by the pulmonologist at Greys 
Hospital, Dr K.T. Naidoo. 
 
Bronchoscopy request forms stored in the bronchoscopy suite were reviewed to 
identify the patients who were eligible for inclusion in the study. Patient‟s medical 
records were reviewed to determine if the inclusion and exclusion criteria were 
met. A total of 129 were reviewed and 107 patients were included in the study. All 
data was extracted from the clinical records and entered on to the case report form 
(Appendix 3) by the principal investigator.  
 
The bronchoscopy reports, in-patient and out-patient hospital clinical records were 
traced and reviewed to capture missing data. Variables that were recorded 
included age, gender, race, referring institution, outcomes and complications of 
bronchoscopy, indication/s for bronchoscopy, human immunodeficiency virus 
(HIV) status, history of antiretroviral therapy (ART) use, previous or current lung 
irritant exposure and the use of protective respiratory equipment, first degree 
relatives with a history of lung malignancy, smoking status, haemoglobin (Hb), 
international normalised ratio (INR) and oxygen saturations.  
 
Indications for bronchoscopy were obtained from a pre-selected list on the 
bronchoscopy request forms. There were no definitions for “non-resolving lower 
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respiratory tract infection (LRTI)” or “diffuse pulmonary infiltrates.” No clear 
distinction could be made between “non-resolving LRTI” and “suspected TB” and 
overlap may exist between the two.  
 
Where data was missing and could not be traced on review of clinical records it 
was indicated as “unknown” on the case report form. Oxygen saturation above 
90% on room air was considered acceptable for the procedure.(5) A Hb level of 
greater than or equal to 10 grams per decilitre (g/dl) was considered safe for 
bronchoscopy, whilst a Hb of less than 10g/dl was considered low. An INR result 
greater than and equal to 1.4 was considered elevated and not suitable to 
undertake biopsy during bronchoscopy. A cluster of differentiation 4 (CD4) count 
of less than or equal to 200 cells per cubic millimetre (cells/mm3) was considered 
to be in keeping with acquired immunodeficiency syndrome and baseline viral 
loads were not routinely requested or recorded. At the time of the study, eligibility 
to commence ART, in South Africa, included a CD4 count of less than 200 
cells/mm3 irrespective of World Health organisation HIV clinical stage, a CD4 
count of less 350 cells/mm3 in pregnant patients or patients with TB/HIV, World 
Health Organisation HIV clinical stage IV disease or MDR TB or XDR TB.(93) 
 
Microbiology, histopathology and cytology results on sputa, broncho-alveolar 
lavage (BAL) samples and biopsy samples were obtained from clinical records, the 
National Health Laboratory Service (NHLS) TrakCare computerised laboratory 
record system or from the relevant laboratory site. When it was uncertain if a 
sample was sent for analysis, it was indicated as “unknown”. For cases where the 
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sample was sent for analysis but no result could be traced it was indicated as “no 
result.” Tuberculosis (TB) was diagnosed on sputum with between one and nine 
acid fast bacilli (AFB) per 100 oil immersion fields (scanty positive), polymerase 
chain reaction (PCR), line probe assay or a TB culture growing mycobacterium 
tuberculosis. GeneXpert®, which is a PCR test, was only available from October 
2011 at this site. 
 
All chest computed tomography (CT) scans were obtained either from the clinical 
records or from the picture archiving and communication system (PACS) 
computerised radiology programme. The chest CT scan reports were all reported 
and authorised by a radiologist.  
 
4.7. Data Management and Analysis 
On completion of all the case report forms the data was entered on an Excel® 
workbook using Microsoft Office 2010® software. The data was thereafter further 
analysed using Epi-info Version 3.5.4® and Stata/IC 13.0® statistical analysis 
computer programmes. The demographic, bronchoscopy and chest CT scan 
findings were summarised with descriptive summary measures and expressed as 
means ± standard deviation (SD) and/or medians with the range for quantitative 
variables. Percentages, frequencies and proportions were used to describe 




The profile of the patients who underwent bronchoscopy was described on a table 
indicating the frequencies of relevant categories pertaining to demographic data 
(age, gender, race, referral centre) and clinical characteristics (family history of 
lung malignancy, HIV status, ART therapy, smoking status and exposure to lung 
irritants). Age was categorised into groups of 10 years and the distribution of age 
was indicated using a bar graph. A table indicating median, SD, range and 95% 
confidence intervals (CI) was constructed for the continuous variables; age, Hb, 
INR, CD4 and oxygen saturation.  
 
The frequency of individual indications for bronchoscopy was determined and 
more broadly classified into infective, non-infective, either infective or non-infective 
(where the aetiology was unclear) or unknown categories (where the indication 
was missing).   
 
The description of the chest CT scan reports was tabulated to indicate the 
frequency. The frequency of microbiological findings on sputa and BAL samples 
were also tabulated. The results of microbiological cultures and TB detection 
methods (Ziehl Nielsen, PCR and TB culture) on sputum and BAL samples were 
compared on a table. 
 
Histology samples were analysed according to benign pathology, malignant 
pathology, no pathological diagnosis, non-representative and no result categories. 
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The demographic and clinical profile of the patients diagnosed with lung cancer 
was tabulated. 
 
Radiological detection of lung mass was compared to the macroscopic 
appearance of lung mass during bronchoscopy. Using bronchoscopy as the more 
accurate means of assessment, the sensitivity, specificity, positive predictive value 
and negative predictive value was calculated.(94)  
 
A comparison was made between the indication for the bronchoscopy and the 
results of the samples collected during bronchoscopy. This was tabulated. The 
data was used to determine the diagnostic outcomes of bronchoscopy.  
 
4.8. Ethical Considerations 
Permission to conduct this retrospective study using clinical record review was 
obtained from the Biomedical Research and Ethics Committee (Reference number 
144/13) (Appendix 4 and 5) at the University of KwaZulu Natal as well as the 
Greys Hospital management (Appendix 6). Each patient was allocated a unique 
study number. Only this unique number was reflected on the case report form to 
maintain patient confidentiality. This link between the study number and the patient 
record was stored separately and will be destroyed on acceptance of the 
dissertation. There was no direct contact between the researcher and the 







5.1. Patient Population 
A total of 129 bronchoscopies were requested between 1 January and 31 
December 2011. Of this, 22 patients were excluded due to failure to meet the 
inclusion criteria. A total of 107 patients met the inclusion criteria of the study and 
















FIGURE 5.1. The sample population; all patients who had bronchoscopy at 
Greys Hospital in 2011 
129 bronchoscopy 
requests 
22 bronchoscopies excluded 
 12 cases not performed in 
bronchoscopy suite 
 6 cases repeated 
 2 cases under 18 years old 





5.2. Baseline Demographic and Clinical Characteristics 
The majority of the patients were indigenous African (70.1%) compared with Indian 
(16.8%), White (11.2%) and Coloured (1.9%) patients. (Table 5.1) There were 
more males (63.6%) than females (36.4%) in the study group. The median age 
was 55±14.4 years and 66% of patients were between 40 and 70 years. (Figure 
5.2)   
 
All of the patients, who were referred from a tertiary institution, were in-patients at 
Greys Hospital (84.1%). The remainder of the patients were from Edendale 
Hospital, a neighbouring regional hospital (13.1%) and Northdale Hospital which 
offers district level services (1.9%). One (0.9%) patient was referred from a 
correctional services facility. (Table 5.1) 
 
Smoking was prevalent in 34.6% of the patients whilst 12.1% had never smoked. 
A smoking history was unknown for 53.3% of the sample group. Information about 
a family history of lung malignancy and exposure to lung irritants was available for 
21.5% of the sample group. (Table 5.1) A positive family history of lung 
malignancy was noted in 5.6% of the study group and 7.5% of the patients had 
been exposed to lung irritants such as gold (1.9%), insecticides (1.9%), diesel 
fumes (0.9%), rubber (0.9%), factory smoke (0.9%) and dust (0.9%). The use of 
respiratory protective equipment during exposure to lung irritants was not 
documented in the case notes hence this information was not available for 
analysis.   
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The human immunodeficiency virus (HIV) status of the study group was unknown 
for 36.4% of the sample group, due to either no recorded HIV status in the case 
records or the patient being unaware of their HIV status at the time of 
bronchoscopy. (Table 5.1) A total of 28 (26.2%) patients were HIV infected with a 
median cluster of differentiation 4 (CD4) count of 254 cells per cubic millimetre 
(cells/mm3) (95%CI 197-324 cells/mm3). (Table 5.2)  
 
A CD4 count of 200 cells/mm3 and below was present in 12 (42.9%) HIV infected 
patients. Nine (32.1%) patients were eligible to commence antiretroviral therapy 
(ART) but were ART naïve at the time of bronchoscopy. Of all the HIV infected 
patients, 10 (35.7%) patients were on ART at the time of bronchoscopy. (Table 
5.2) The median CD4 count for those on ART was 248 cells/mm3 (95%CI 161-331 












TABLE 5.1: Baseline demographic and clinical findings of the study patients 
(N=107), who had a bronchoscopy at Greys Hospital, in 2011 
 




  Age (years) 
    21 – 40 23 21.5 
    41 – 70 71 66.4 
    >=70 13 12.2 
  Gender 
     Male 68 63.6 
     Female 39 36.4 
  Race 
     African 75 70.1 
     Indian 18 16.8 
     White 12 11.2 
     Coloured 2 1.9 
  Referral Centre 
     Tertiary 90 84.1 
     Regional 14 13.1 
     District 2 1.9 
     Other 1 0.9 
Risk factors for lung pathology 
  Smoking status 
     Never smoked 13 12.1 
     Ever smoker  37 34.6 
     Unknown smoking 
history 
57 53.3 
  Family history of lung malignancy 
     Yes 6 5.6 
     No 17 15.9 
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     Unknown 84 78.5 
  Exposure to lung irritants 
     Present 8 7.5 
     Absent 15 14 
     Unknown 84 78.5 
  HIV status 
     Infected 28 26.2  
     Uninfected 40 37.4 
     Unknown 39 36.4 
  Antiretroviral drug therapy 
     Regimen 1* 9 32.1 
     Regimen 2** 1 3.6 
     Not on treatment 18 64.3 
 
*Regimen 1: two nucleoside reverse transcriptase inhibitor (NRTI) and non-
nucleoside reverse transcriptase inhibitor (NNRTI):  
Lamivudine, Tenofovir, Efavirenz (4 cases) 
Lamivudine, Stavudine, Efavirenz (3 cases) 
Lamivudine, Stavudine, Nevirapine (1 case) 
Lamivudine, Zidovudine, Efavirenz (1 case) 
**Regimen 2: two nucleoside reverse transcriptase inhibitors (NNRTI) and one 
protease inhibitor (PI): 
Lamivudine, Tenofovir, Lopinavir/Ritonavir (1 case) 
Abbreviations- HIV: Human immunodeficiency virus, NRTI: Nucleoside reverse 






TABLE 5.2: Laboratory safety and clinical investigations performed on the 
patients prior to bronchoscopy procedure 
PARAMETER MEDIAN (SD)   RANGE 95%CI Inter-quartile 
Range 
  Haemoglobin 
(g/dl) 
11.8 ±2.11 6.8 - 16.5 11.23 - 12.04 10.4-13.1 
  INR 1.09 ± 0.19 0.9 - 2.11 1.09 - 1.17 1.02-1.19 
  CD4 of all HIV 
infected 
(cells/mm3) 
254 ±164 52 - 665 197 - 324 126-366.5 
  CD4 of 
patients on ART 
(cells/mm3) 
248 ± 126 52 - 445 161 - 331 152-325.5 
  Oxygen 
Saturation (%) 
99 ±1.93 91 - 99 97.58 - 98.42 97-99 
 
Abbreviations- ART: Antiretroviral therapy, Cells/mm3: Cells per cubic millimetre, 
CD4: Cluster of differentiation 4, CI: Confidence interval, g/dl: Grams per decilitre, 












21-30 2 6 
95%CI 35.0-85.0 40.35-109.65 
31-40 10 5 
95%CI 37.86-96.14 8.22-74.22 
41-50 14 6 
95%CI 46-94 6.67-77.7 
51-60 18 8 
95%CI 47.63-90.27 1.05-63.05 
61-70 16 9 
95%CI 40.48-87.52 4.64-67.36 
71-80 7 5 
95%CI 21.44-94.56 1.26-85.26 
>80 1 0 
95%CI 0  
 
FIGURE 5.2: Distribution of age of the patients who had bronchoscopy at 
Greys Hospital in 2011  
















5.3. Pre-procedure Laboratory Investigations 
A haemoglobin (Hb) result was available for all patients prior to bronchoscopy. An 
Hb of greater than or equal to 10 grams per decilitre (g/dl), which was considered 
safe for bronchoscopy, was present in 86 (80.4%) patients. The median Hb was 
11.8g/dl (95%CI 11.23-12.04 g/dl). (Table 5.2) It is unknown if the 21 (19.6%) 
patients with Hb less than 10g/dl received a blood transfusion prior to 
bronchoscopy.  
 
An INR result was available for 104 patients. Of this, 98 patients (91.6%) had an 
INR result less than or equal to 1.4 and 6 patients (5.6%) had a high INR of 
greater than 1.4. The median INR was 1.09 (95%CI 1.09-1.17). (Table 5.2) 
Bronchoscopy was still performed on the patients with an elevated INR result, but 
the biopsy was deferred. If a biopsy was necessary, bronchoscopy was repeated 
when the INR result was normal. This was done for one patient in the cohort. One 
patient who had an INR result of 2.1 was on enoxaparin and warfarin for the 
treatment of deep venous thrombus. It was unclear as to why the other INR results 
were elevated. 
 
Pre-bronchoscopy oxygen saturations were documented for 84 (78.5%) patients 
and all readings were greater than or equal to 90%. The median saturation was 
99% (95%CI 97.58- 98.42%). (Table 5.2) 
 
5.4. Pre-bronchoscopy Chest Computed Tomography Scan 
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A chest computed tomography (CT) scan was done prior to bronchoscopy as it 
defines the lung anatomy and assists with localising the lung lesions.(95) This 
assists with improving the diagnostic yield of bronchoscopy.(95) A chest CT scan 
was performed for 66 (61.7%) patients, either at Greys Hospital or at the referral 
centre. (Table 5.3) A total of 36 (54.5%) reports stated that the radiographic 
findings were likely to be in keeping with a non-benign process with 30 (45.5%) 
reports describing a mass lesion, either alone or accompanied by other pathology. 
There were 19 reports (28.8%) of possible lung metastases. 
 
The remaining 30 (45.5%) chest CT scans reported pathology that was likely to be 
related to a benign process. There were eight (12.1%) reports concluding a 
diagnosis of bronchiectasis, eight (12.1%) of cavitation and five (7.6%) reported 
lung opacification. There was one (1.5%) chest CT scan reported as normal. The 
indication for bronchoscopy in this patient was unclear as the clinical records were 










TABLE 5.3: Frequency of computed tomography (CT) scan (N=66) of the 
chest, performed prior to bronchoscopy at Greys Hospital in 2011  




Mass 30 45.5 
Metastases 19 28.8 
Lymphadenopathy 16 24.2 
Nodules 7 10.6 





Bronchiectasis 8 12.1 
Cavitation 8 12.1 
Opacification 5 7.6 
Fibrosis 4 6.1 
Interstitial pattern 3 4.5 
Other 10  
    Abscess 2 3.0 
    Bullous 2 3.0 
    Emphysema 2 3.0 
    Granuloma 2 3.0 
    Cyst 1 1.5 
    Haemothorax  1 1.5 
Normal 1 1.5 
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TOTAL 113* 100 
 
*The total exceeds 66 as more than 1 finding was evident on the chest CT scans.  
Abbreviations- CT: Computed tomography 
 
5.5. Indications for and Findings at Bronchoscopy 
The commonest indications for bronchoscopy were non-infective (36%) rather than 
infective pathologies (32%). (Figure 5.3) Non-infective pathology included lung 
mass (35.8%) and trachea-oesophageal fistula (0.8%), whilst infective pathology 
included non-resolving LRTI (15%), suspected tuberculosis (TB) (15%) and lung 
abscess (1.7%). Diffuse pulmonary infiltrates (12.5%) and haemoptysis (9.2%) 
were categorised as either infective or non-infective as the aetiologies were 
unclear at the time of request. There was more than one indication listed for some 
patients resulting in the total number (120) of indications exceeding the number of 
bronchoscopies performed (107). Overall the commonest indications for 
bronchoscopy were lung mass (35.8%), non-resolving LRTI (15%) and suspected 
TB (15%). (Table 5.4) 
 
The commonest diagnoses by bronchoscopy were made in the patients referred 
for investigation of diffuse pulmonary infiltrates. Of the 15 patients referred, 
bronchoscopy assisted with the diagnosis in seven (46.7%) patients; two (13.3%) 
patients had positive bacterial cultures, three (20%) patients had positive fungal 
cultures, one (6.7%) patient had TB and one (6.7%) patient had chronic interstitial 
fibrosis on biopsy. (Table 5.4) 
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The second highest diagnostic yield was in patients referred for investigation of a 
lung mass. Of the 43 patients referred 20 (46.5%) bronchoscopy diagnoses were 
made. Thirteen (30.2%) had lung cancer, one (2.3%) had a positive bacterial 
culture, one (2.3%) had a positive fungal culture, one (2.3%) had TB, one (2.3%) 
had non-specific granulation tissue and three (7%) had no pathology. (Table 5.4)   
 
Bronchoscopy assisted with achieving a diagnosis in five (27.8%) of the 18 
patients referred for non-resolving LRTI. Of these five patients; three (16.7%) 
patients had a positive bacterial culture, one (5.6%) patient had a positive fungal 
culture and one (5.6%) patient had lung cancer. (Table 5.4) 
 
Of the 18 patients referred for investigation of suspected TB, bronchoscopy 
assisted with the diagnosis on four (22.2%) of the 18 patients. Two (11.1%) 
patients had positive fungal cultures, one (5.6%) patient had TB and one (5.6%) 
patient had lung cancer. (Table 5.4) 
 
Two (18.2%) of the 11 patients referred with haemoptysis had lung cancer, one 
(9.1%) patient had acute bacterial pneumonia on endo-bronchial biopsy and one 




















INDICATIONS FOR BRONCHOSCOPY 
Infective
Non-Infective





TABLE 5.4: Frequency of indications and findings of bronchoscopy at Greys 
Hospital in 2011 
























18 (100) 3 (16.7) 1 (5.6) 0 1 (5.6) 0 13 (72.2) 
Suspected 
Tuberculosis 
18 (100) 0 2 (11.1) 1(5.6) 1 (5.6) 0 14 (77.8) 
Diffuse pulmonary 
infiltrates 
15 (100) 2 (13.3) 3 (20) 1(6.7) 0 1 (6.7) 8 (53.3) 
Unclear indication 12 (100) 1 (8.3) 1 (8.3) 1 (8.3) 0 0 9 (75) 
Haemoptysis 11 (100) 0 0 0 2 (18.2) 2 (18.2) 7 (63.6) 
Other 3 (100) 0 0 0 0 0 3 (100) 
   Lung abscess 2 (100) 0 0 0 0 0 0 
   Tracheo-
oesophageal fistula 
1 (100) 0 0 0 0 0 0 















*The total of 120 exceeds the sample size of 107 as more than one indication per 
patient was present 
 
5.6. Microbiological Findings on Sputa Samples Prior to Bronchoscopy 
Microscopy, culture and sensitivity (MC&S) of sputa samples were requested on 
48 patients prior to bronchoscopy request. (Table 5.5) There was growth of 
organisms on 11 (22.9%) samples. Seven (14.6%) gram negative bacterial 
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organisms were cultured namely; Klebsiella pneumoniae which was identified in 
two (4.2%) patients and Haemophilus influenza, Pseudomonas aeruginosa, 
Citrobacter koseri, Lecercia adenocarboxylate, Morganella morganii and Proteus 
mirabilis which was identified in six (12.5%) different patients respectively. There 
was one (2.1%) gram positive bacillus cultured; Staphylococcus aureus (sensitive 
to cloxacillin) and two (4.2%) fungal cultures of Candida albicans. On 26 (54.2%) 
samples there was no growth and 11 (22.9%) results could not be traced.  
 
Of the patients with a positive bacterial or fungal culture, three were HIV infected, 
four were HIV uninfected and four patients had an unknown HIV status. The HIV 
infected patients‟ cultured Klebsiella pneumoniae, Haemophilus influenza and 
Staphylococcus aureus. Only one patient had a CD4 count available (52 
cells/mm3) and this patient was on antiretroviral therapy (ART).  
 
TB screening was performed using either Ziehl Neelsen or auramine stains. Fifty 
samples (98%) stained negative and one (2%) sample leaked and was discarded. 
(Table 5.5) None of the samples stained positive for acid fast bacilli (AFB). Eight 
samples were sent for polymerase chain reaction (PCR) identification using either 
GeneXpert® or line probe assay (LPA). Of these, three (37.5%) samples were 
negative and five (62.5%) were positive for TB. One of the five positive PCR tests 
suggested rifampicin resistance and extreme drug resistant TB (XDR TB) on TB 




TB culture was requested in 39 patients. The results were only available post 
bronchoscopy and showed that 32 (82.1%) samples were negative and seven 
(17.9%) were positive for TB. (Table 5.5) Six (15.4%) samples were sensitive to 
rifampicin and isoniazid. One (2.6%) sample was resistant to isoniazid, rifampicin, 
streptomycin, kanamycin and ofloxacin suggesting XDR TB.  
 
TABLE 5.5: Frequency of microbiological findings on sputum samples 
collected prior to bronchoscopy 










48 51 8 39 
Positive 11 (22.9%) 0 (0%) 5 (62.5%) 7 (17.9%) 
Negative 26 (54.2%) 50 (98%) 3 (37.5%) 32 (82.1%) 
Could Not Be 
Traced 
11 (22.9%) 1 (2%) (leaked) 0 (0%) 0 (0%) 
 
Abbreviations- LPA: Line probe assay, MC&S: Microscopy, culture and sensitivity, 
PCR: Polymerase chain reaction, TB: Tuberculosis, ZN: Ziehl Neelson 
 
5.7. Microbiological Findings on Broncho-alveolar Lavage  
There were 43 BAL samples requested for MC&S. (Table 5.6) Bacterial growth 
was present on six (14%) samples. Staphylococcus aureus, sensitive to cloxacillin, 
was identified on one (2.3%) sample which was not on the same individual who 
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cultured the organism on sputum. Haemophilus influenzae was identified on two 
(4.7%) samples. Other gram negative organisms isolated included Klebsiella 
pneumonia, Pseudomonas aeruginosa and Serratia marcesans. There was no 
growth on 24 (55.8%) samples. Results could not be traced for 13 (30.2%) 
patients.   
 
Of the patients with positive bacterial cultures on BAL samples, three patients 
were HIV infected whilst one patient was uninfected. The HIV status of two 
patients was unknown. The three HIV infected patients‟ cultured Haemophilus 
influenzae (two patients) and Klebsiella pneumoniae (one patient). The two HIV 
infected patients with Haemophilus influenzae had CD4 counts of 419 cells/mm3 
and 108 cells/mm3 respectively and were on ART. The CD4 count of the HIV 
infected patient with Klebsiella pneumoniae was unknown and the patient was 
ART naïve. 
 
Fungal culture was requested on 30 samples. Growth was identified on six (20%) 
samples with one (3.3%) sample showing growth of two fungal organisms; 
Aspergillus flavus and Candida albicans. The other organisms identified were 
Aspergillus niger (one patient), Candida albicans (three patients) and 
Cryptococcus neoformans (one patient). Of the remaining samples, seven (23.3%) 
had no growth, two (6.7%) were not done due to a laboratory error and 15 (50%) 




Of the positive fungal cultures, one patient was HIV infected, two were HIV 
uninfected and three had an unknown HIV status. The one patient who was HIV 
infected and cultured Aspergillus niger, had an unknown CD4 count and was ART 
naïve.  
 
Samples were requested for Pneumocystis jirovecii in 17 patients. The results 
were negative in 10 (58.8%) patients and the remainder of the results could not be 
traced. (Table 5.6) 
 
BAL samples were sent for AFB analysis for 38 patients. (Table 5.6) AFB was 
observed in two (5.3%) samples. Both these patients were HIV infected. The CD4 
count of one patient was 270 cells/mm3 and this patient was not on ART. The 
other patients CD4 count was 141 cells/mm3 and it was unknown if this patient 
was on ART. Results were negative in 22 (57.9%) samples and the remaining 14 
(36.8%) samples could not be traced.  
 
Seven samples were sent for PCR either using GeneXpert® or LPA. Of these, 
three (42.9%) were positive, two (28.6%) were negative, one (14.3%) sample 
leaked and no result could be traced for the remaining sample (14.3%). Of the 
three patients with a positive PCR test, the HIV status of two patients were 
unknown. The third patient also had a positive AFB result, was HIV infected, had a 
CD4 count of 270 cells/mm3 and was ART naive. All three (42.9%) of the samples 
that were positive on PCR were sensitive to rifampicin and isoniazid. 
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BAL samples were also sent for TB culture for 35 patients. (Table 5.6) Results 
were positive for three (8.6%) samples (two of these samples were already 
positive on the PCR test; one patient with an unknown HIV status and the other 
patient was HIV infected, CD4 270 cells/mm3 and was ART naive). Both these 
samples were sensitive to rifampicin and isoniazid. The third patient cultured 
mycobacterium other than tuberculosis. This third patient was HIV infected, had a 
CD4 count of 141 cells/mm3 and had an unknown ART history. TB culture was 
negative for 18 (51.4%) samples. The results of 14 (40%) samples could not be 
traced.  A total of four (11.4%) patients were diagnosed with TB using AFB, PCR 













TABLE 5.6: Frequency of microbiological findings on broncho-alveolar 
lavage collected at the time of bronchoscopy  





43 30 17 38 7 35 









































Abbreviations- AFB: Acid fast bacilli, LPA: Line probe assay, MC&S: Microscopy, 
culture and sensitivity, PCR: Polymerase chain reaction, PCP: Pneumocystis 
jirovecii pneumonia, TB: Tuberculosis 
 
5.8. Comparison between Sputum and Broncho-alveolar Lavage 
Microbiological Culture 
When the sputum and BAL microbiological cultures were compared, the same 
organism was cultured on only one patient. This was for Pseudomonas 
aeruginosa. There were 10 (20.8%) samples where the organism was only 
cultured on sputum and 12 (11.6% bacterial and 20% fungal) samples where it 




Amongst sputum smear negative patients, two (5.7%) cases were positive for AFB 
on BAL samples. PCR was positive in both sputum and BAL samples for one 
(2.85%) patient. One (2.85%) patient had a positive TB culture on sputum whilst 
the BAL culture was negative. This patient had XDR TB and was on appropriate 
treatment for an unknown duration when BAL was performed. Another patient had 


















TABLE 5.7: Diagnosis of TB amongst sputum and broncho-alveolar 
sampling performed on the sample population 
 SPUTUM BAL 
 ZN PCR TB 
Culture 




Negative Positive Positive No result Not 
requested 
Negative 
2. Negative Positive Positive Positive Positive Positive 
3. Negative Not 
requested 
Positive Negative Negative No result 







































No result Positive Positive 
10. Negative Not 
requested 
Negative Positive Not 
requested 
Positive 




No result Positive Not 
requested 
Abbreviations- BAL: Broncho-alveolar lavage, PCR: Polymerase chain reaction, 
XDR TB: Extreme drug resistant tuberculosis, ZN: Ziehl Neelson 
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5.9. Cellular Findings on Sputa and Broncho-alveolar Lavage 
Cytology was requested on sputa and BAL samples. There were 40 sputa 
samples sent for cytology. Atypical cells were present on three (7.5%) samples 
and one (2.5%) of these was noted as squamous cell carcinoma (SCC). All three 
sputa samples with atypical cells had normal BAL cytology and biopsy results. No 
malignant cells were present in 17 (42.5%) samples; six (15%) samples were 
unrepresentative, whilst 14 (35%) results could not be traced.  
 
BAL samples for cytology were requested for 61 samples. There were atypical 
cells present on eight (13.1%) samples: one (1.6%) with SCC, one (1.6%) with 
adenocarcinoma, one (1.6%) with reactive bronchial cells and five (8.2%) with 
atypical cells. Both BAL cytology samples suggestive of lung cancer were proven 
on biopsy. Of the five (8.2%) patients with atypical cells on BAL cytology: two 
(3.3%) patients had SCC on biopsy, one (1.6%) patient had atypical cells on 
biopsy also, and two (3.3%) patients had no biopsy taken. The one (1.6%) patient 
with reactive bronchial cells on BAL cytology had no biopsy taken. There were no 
malignant cells on 37 (60.7%) samples and no result could be traced for 16 
(26.2%) samples. 
 
5.10. Macroscopic Appearance on Bronchoscopy 
During the bronchoscopy procedure, there were 23 (53.5%) cases were a mass 
was visible macroscopically. In addition, there were nine (8.4%) cases were 
external compression of the airway was visible suggesting that a lung 
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parenchymal mass was present. When the macroscopic appearance of 
bronchoscopy was compared to chest CT findings; bronchoscopy detected 
masses in an additional 76.6% of patients. With bronchoscopy used as the gold 
standard test, the sensitivity and specificity of chest CT scan for detection of lung 
masses was 73.7% and 70% respectively. The positive predictive value and 
negative predictive value were 46.7% and 86.1% respectively. 
 
5.11. Histological Findings on Biopsy 
The decision to undertake biopsy was dependent on the macroscopic findings and 
accessibility of the lesion during bronchoscopy. There were 27 (25.2%) biopsy 
samples sent for histology. (Table 5.8) From these 16 (59.2%) malignant 
pathologies and three (11.1%) benign pathologies were identified. The malignant 
pathologies included 10 SCC (37%), two adenocarcinomas (7.4%), three 
carcinomas of unknown origin (11.1%) and one sample of atypical cells (3.7%). 
These atypical cells could not be further differentiated. Of the three unknown 
carcinoma samples: one specimen had features resembling adenocarcinoma and 
a neuroendocrine tumour, the second specimen was likely to be SCC and the third 
sample the carcinoma could not be differentiated. The ratio of SCC: 
adenocarcinoma diagnosed was 5:1. 
 
The three benign pathologies identified included acute bacterial pneumonia, 
chronic interstitial fibrosis and non-specific granulation tissue. No organism was 
identified on the biopsy sample with pneumonia, but gram negative cocci were 
reported. Sputum and BAL MC&S for this patient were also inconclusive. There 
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were three (11.1%) samples for which no pathological diagnosis could be made, 
two (7.4%) samples that were non representative and three (11.1%) samples 
where no result could be traced. (Table 5.8) 
 
TABLE 5.8: Frequency of histological findings of lung biopsy (N=27) 
obtained during bronchoscopy at Greys Hospital in 2011 
HISTOLOGY FREQUENCY(N=27) PERCENTAGE (%) 
Malignant Pathology  
  Squamous cell carcinoma 10 37.0 
  Adenocarcinoma 2 7.4 
  Carcinoma (uncertain type) 3 11.1 
  Atypical cells 1 3.7 
Benign Pathology 
  Acute bacterial pneumonia 1 3.7 
  Chronic interstitial fibrosis 1 3.7 
  Non-specific granulation 
tissue 
1 3.7 
No pathological diagnosis 3 11.1 
Non-representative 2 7.4 
No result  3 11.1 







5.12. Demographic and Clinical Profile of Patients with Lung Cancer 
The mean age of males with lung cancer was 57.8 years whilst for females it was 
63.7 years. Overall lung cancer was more common in males than females (4:1) 
and was associated mainly with the indigenous African population compared to 
other races. (Table 5.9) A family history of lung malignancy was noted in one 
(6.25%) patient with SCC and one (6.25%) patient with unknown carcinoma. Two 
(12.5%) patients had exposure to lung irritants; one (6.25%) with SCC had 
exposure to gold and the other (6.25%) with unknown carcinoma had exposure to 
insecticides. Unfortunately, use of respiratory protective equipment during 
exposure to lung irritants for these two patients was unknown. None of the patients 
with lung cancer were HIV infected.   
 
More patients who smoked were diagnosed with cancer. The ratio between 










TABLE 5.9: Demographic and clinical profile of 16 patients with confirmed 
lung cancer 
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Abbreviations- HIV: Human immunodeficiency virus. SCC: Squamous cell 
carcinoma 
 
5.13. Summary of Outcomes of Bronchoscopy 
The three most common indications for bronchoscopy were suspected lung mass, 
non-resolving LRTI and suspected TB. However, bronchoscopy confirmed the 
most diagnoses in 7 of 15 patients (46.7%) referred with diffuse pulmonary 
infiltrates. Bronchoscopy also confirmed the histological diagnosis in 20 of 43 
patients (46.5%) referred for suspected lung mass, 5 of 18 (27.8%) patients 
referred for investigation of non-resolving LRTI, and 4 of 18 patients (22.2%) 
referred for suspected TB. (Table 5.4) 
 
Bronchoscopy assisted with the diagnosis of broncho-respiratory pathology in 38 
(35.5%) patients. No pathological diagnosis could be made for 46 (43%) patients. 
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There were 23 (21.5%) patients where no diagnosis could be made due to missing 
BAL results.  
 
5.14. Complications related to Bronchoscopy 
There were four (3.7%) patients who experienced procedure related 
complications.  Three (75%) patients experienced oxygen desaturation during 
bronchoscopy and responded well to supplemental oxygen. One (25%) patient 
had haemoptysis post biopsy but the volume of blood loss was not documented. 
All patients recovered without further complications. 
  
5.15. Summary of Results 
The most common indications for bronchoscopy were investigation of a lung mass, 
non-resolving LRTI and suspected TB. Bronchoscopy assisted with 
microbiological, cytological or histological diagnosis of broncho-respiratory 
pathology in 35.5% of all patients in the study. Bronchoscopy confirmed infection 
in the majority of patients referred for investigation of diffuse pulmonary infiltrates. 
Microbiological findings on sputum and BAL revealed gram positive and negative 
cocci and fungi. Cytological findings on sputum were inconsistent with that of BAL 
samples. Cytology on BAL samples detected lung malignancy in 3.3% of cases 
which was confirmed on biopsy. Only 11.1% (two of 18 patients) of smear negative 
TB suspects had a diagnosis of TB confirmed by bronchoscopy. Squamous cell 
carcinoma was the commonest lung cancer detected by histology. Overall the 
bronchoscopy complication rate was 3.7%. 
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When the macroscopic appearance of bronchoscopy was compared to chest CT 
findings; bronchoscopy detected masses in an additional 76.6% of patients. With 
bronchoscopy used as the gold standard test, the sensitivity and specificity of 
chest CT scan for detection of lung masses was 73.7% and 70% respectively. The 



















   
Our study explored the outcomes of bronchoscopy over a one year period, at 
Greys Hospital. The objectives of our study were to describe bronchoscopy 
indications and microbiological, cellular and histological findings on bronchoscopy 
samples. The prevalence of TB diagnosed on broncho-alveolar lavage (BAL) 
amongst smear negative patients, in this high TB/HIV prevalence area, and the 
common types of lung cancer diagnosed on biopsy during bronchoscopy, were 
also described. This was the first study in Pietermaritzburg describing outcomes of 
bronchoscopy in the public sector.   
 
The key findings of the study were that bacterial cultures, fungal cultures and 
cytology performed on broncho-alveolar lavage (BAL) samples assisted with 
achieving a microbiological or cytological diagnosis where sputum microscopy, 
culture or cytology could not. Microscopy, polymerase chain reaction (PCR) and 
TB culture on BAL specimens were useful means for TB detection amongst 
sputum smear negative patients. Squamous cell carcinoma (SCC) and 
adenocarcinoma were the two most common lung cancers diagnosed on 
histology. 
 
6.1. Indications for Bronchoscopy 
91 
 
There is a scarcity of studies describing indications for bronchoscopy in South 
Africa. A study from Cape Town listed suspected lung malignancy and TB as the 
two most common indications for bronchoscopy.(31) The findings of our study are 
similar as suspected lung mass was the most common indication for 
bronchoscopy followed by an equal proportion of requests for non-resolving lower 
respiratory tract infection (LRTI) and suspected TB. Non-resolving LRTI could not 
be defined in our study and there may be significant overlap between this 
indication and that of suspected TB. Despite this, the results were also 
comparable to studies in the United States of America (15) and Middle East where 
infection and suspected lung malignancy were also the most common indications 
for bronchoscopy.(16, 17, 30) 
 
6.2. Pre-Bronchoscopy Chest Computed Tomography Scan on Suspected 
Lung Cancer Patients 
The value of chest computed tomography (CT) scan in lung cancer detection 
remains controversial. The sensitivity and specificity of lung mass detection on 
chest CT scan compared to bronchoscopy in this study was 73.7% and 70% 
respectively. The National Lung Screening Trial reported a higher sensitivity and 
specificity of 93.8% and 73.4% respectively for low dose CT scan at detecting lung 
cancer.(78) In the National Lung Cancer Screening Trial, however, not all patients 
enrolled had a bronchoscopy and biopsy and histological confirmation of lung 
cancer was by analysis of specimens obtained during mediastinoscopy, 
thoracoscopy, thoracotomy or percutaneous trans-thoracic or extra-thoracic 
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access.(78) This may have accounted for the higher sensitivity and specificity in 
the National Lung Cancer Screening Trial.  
 
The National Lung Cancer Screening Trial demonstrated a positive and negative 
predictive value of 3.8% and 99.9% respectively.(78) The trial was associated with 
a large number of false positives contributing to the low positive predictive 
value.(78) A study by Lecourtois B et al, also demonstrated that low dose chest 
CT screening for lung cancer may be associated with false positive rates of 
43%.(85) In our study, the positive and negative predictive values were 46.7% and 
86.1% respectively. However, in our study, low dose chest CT scan was not used. 
Chest CT scans were performed and reported on by different radiology 
departments, depending on the referral hospital, and not all patients referred for 
bronchoscopy with a suspected lung mass had a chest CT scan. Nevertheless, the 
results of our study suggest that chest CT scan is a valuable rule out test, and 
should not be used in isolation for the diagnosis of lung cancer. 
 
6.3. Findings at Bronchoscopy 
6.3.1. Microbiological Findings on Bronchoscopy 
The microbiological cultures on BAL demonstrated a variety of organisms 
including gram positive and negative bacilli and fungi. In South Africa, community 
acquired pneumonia in immune-competent patients is commonly caused by 
Streptococcus pneumoniae, Klebsiella pneumoniae and Haemophilus 
influenzae.(3) Community acquired pneumonia in immune-compromised patients 
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is caused by opportunistic pathogens namely; Mycobacterium tuberculosis, 
Pneumocystis jiroveccii and invasive fungi such as Aspergillus fumigatus.(3) 
Microbiology of nosocomial pneumonia in South Africa implicates; Streptococcus 
pneumoniae, Haemophilus influenza, Staphylococcus aureus, Moraxella 
catarrhalis, Enterobacter species (spp), Klebsiella spp, Proteus spp, Serratia 
marcescens, Pseudomonas spp and Acinetobacter spp in its aetiology.(96) 
Therefore, none of the microbiological findings on bronchoscopy, in our study, 
were unexpected. All bacteria cultured on BAL, have been recognised as common 
respiratory pathogens in South Africa, according to local community acquired 
pneumonia and nosocomial pneumonia guidelines.(3, 96) 
   
A study examining the use of BAL in immune-compromised hosts, identified 
Pneumocystis jirovecii (50%), Aspergillus spp (25%) and Candida albicans in the 
cohort.(97) Pneumocystis and Aspergillus were pathogenic in 50% and 25% of 
cases respectively whilst Candida was found to be a coloniser and not a 
pathogen.(97) In our study, Candida albicans was cultured on four samples. Due 
to the retrospective nature of our study, it was unclear from available records 
whether Candida albicans was a coloniser or a pathogen as all patients with 
positive cultures were HIV uninfected or HIV status unknown and other reasons for 
immunosuppression were not explored.   
 
Another study, conducted in Uganda amongst HIV infected, smear negative 
patients cultured Pneumocystis jirovecci and Cryptococcus neoformans on 
BAL.(8) At this site, Cryptococcus neoformans and Candida albicans were 
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detected in two HIV uninfected patients. Other aetiologies of immunosuppression 
and risk factors for cryptococcosis could not be definitively excluded on review of 
the clinical records. Although fungal culture on BAL is associated with 
immunosuppression, infrequently it may occur in immune-competent 
individuals.(98) There was insufficient information available to conclude if the fungi 
cultured in our study were among immune-compromised or competent individuals.  
 
The use of bronchoscopy in the detection of TB has been described in literature 
for over 30 years.(7) Detection rates using acid fast bacilli (AFB) and TB culture on 
BAL and trans-bronchial needle biopsy samples vary from 30% to 83%.(9, 16). 
These detection rates were calculated as the percentage of TB detected on 
bronchoscopy amongst TB suspects and were not performed exclusively on smear 
negative patients. In our study, BAL samples were analysed for AFB, PCR and TB 
culture and no trans-bronchial needle biopsies were performed. The detection rate 
of TB using these three tests was 22.2%, which is lower than that reported in other 
studies. A study from Cape Town, South Africa, described TB diagnosis in 67.4% 
of smear negative patients only from bronchial brushings and trans-bronchial 
biopsy.(7) BAL samples were not used to make a diagnosis of TB as was used in 
our study. Although TB bronchoscopy did not assist significantly with TB diagnosis 
in our study, it is still a valuable tool in the diagnosis of smear negative TB.(7, 8) 
 
Possible reasons for a low TB detection in our retrospective study may include; a 
low suspicion of smear negative TB at peripheral referring hospitals or non-referral 
of patients as empiric TB treatment may be commenced without microbiological 
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confirmation. This may have resulted in a smaller sample group being referred for 
further TB investigation in this area. Other considerations include a relatively 
healthy sample population even amongst HIV infected patients. The median 
cluster of differentiation 4 (CD4) count of 254 ±164 cells per cubic millimetre 
(cells/mm3) was high and hence TB was less likely to be the cause of the lung 
pathology. 
 
6.3.2. Cytological Findings on Bronchoscopy 
The results of cytological analysis were non-specific. Cytological examination of 
BAL samples detected pathology in 13.1% of all samples analysed. A definitive 
diagnosis of SCC was only made on 2.5% of cases and the remaining samples 
were inconclusive. Although the National Institute for Health and Clinical 
Excellence (NICE) and American College of Chest Physicians (ACCP) guidelines 
mention that sputum cytology is not routinely advocated due to a low yield, there is 
no recommendation about cytological analysis on BAL samples.(52, 75) Three 
studies suggest that the test may be of value with 33%, 42.6% and 46% of cases 
detecting lung cancer.(99-101) It was unclear how these detection rates were 
calculated. Our study had a very low detection rate (3.3%), for lung cancer 
compared to other studies. The reasons for this are unclear. 
 
6.3.3. Histological Findings on Bronchoscopy 
Squamous cell carcinoma (SCC) was the most frequent malignant finding on 
histology. Large, multicentre Egyptian and Scottish studies reviewing 3 980 and 2 
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238 bronchoscopies respectively, demonstrate a 70% and 78% diagnostic yield of 
lung cancer.(17, 102)  In the Scottish study, multiple biopsy specimens were 
taken, which may have contributed to this higher yield of malignancy on 
biopsy.(102) Where a „frank tumour‟ was seen on bronchoscopy, histological 
confirmation ranged between 80% and 95%, whereas lesions viewed as „possible 
malignant or normal‟ confirmed only 4% of malignancy.(102) In other studies from 
Singapore, London, England, United States and Norway suggest a wide range of 
diagnostic yields of lung cancer with a range of  22.4% to 88% diagnosed on 
biopsy.(100, 103-105) Discrepancies in detection rates may be attributed to 
differences in sample sizes, demographics, risk factors and number of biopsy 
samples taken.  
 
Our study demonstrates a 46.5% diagnostic yield of malignancy on bronchoscopy. 
It is unknown how many biopsy samples were taken during each bronchoscopy 
and this may have negatively affected the diagnostic yield. Other reasons for the 
yield of this study being lower than other studies may include technical difficulties 
in accessing the tumours during bronchoscopy. 
 
In our retrospective sample one patient worked on a gold mine and was therefore 
at risk for silicosis. It is unclear if there is an exposure-response relationship 
between lung cancer and silicosis.(62, 106) Hypothesized theories include that 
silicosis may lead to inflammation of lung parenchyma with metaplastic 
changes.(106) There was no evidence of silicosis in the patient who worked on a 
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gold mine and it remains unclear if occupational exposure to silica dust was a risk 
factor for lung cancer.  
 
6.4. Tuberculosis Diagnosis and Broncho-alveolar Lavage in Sputum Smear 
Negative Patients 
Tuberculosis is the leading cause of mortality in HIV infected and uninfected South 
Africans.(2) The diagnosis of TB is particularly challenging when sputum for AFB 
is negative but a high index of suspicion for TB infection remains.(37, 107) 
Analysis of BAL for AFB or TB culture has been very useful in TB diagnosis.(46, 
108-110) Detection of AFB on BAL samples ranges between 12% and 26% (46, 
108-111). TB detection using culture performed on BAL samples ranges between 
25% and 30%.(16, 46)  
 
Despite our study being conducted in a high TB/HIV prevalence area, the 
detection of TB on bronchoscopy was low. BAL for AFB had a yield of 11.1% in 
smear negative patients. The mean CD4 count of HIV individuals in this study was 
254 ±164 cells/mm3. These HIV infected individuals were therefore relatively 
“healthy” and did not have TB. This suggests healthy user bias. Referral bias 
whereby all TB suspects with a negative smear were not appropriately referred 
and survival bias whereby smear negative TB patients died prior to referral, may 




GeneXpert® performed on BAL samples offers the advantages of a reduced time 
to diagnosis, early identification of rifampicin resistance and a higher sensitivity 
than sputum smears and culture.(47) In a study conducted in Cape Town, the 
sensitivity of GeneXpert® performed on BAL samples, amongst smear negative 
cases, was 60%.(47) A negative predictive value of 15% was found in those with 
HIV infection.(47) As our study was conducted in 2011 and GeneXpert® was not 
available for the entire study period, the value of GeneXpert® in bronchoscopy 
specimens, at this site, could not be assessed.   
 
6.5. Common Types of Lung Cancer on Biopsy 
Squamous cell carcinoma was the most frequently diagnosed lung cancer, 
followed by adenocarcinoma. The findings in our cohort are similar to study 
findings in Bloemfontein and Johannesburg where SCC was more common than 
adenocarcinoma.(18, 19) In Cape Town, however, adenocarcinoma was the most 
commonly diagnosed lung malignancy.(20) Internationally, the histological 
subtypes of lung cancer vary geographically, with adenocarcinoma more common 
in North America(75) and SCC more common in Algeria, Tunisia, Morocco and 
Kuala Lumpur.(103, 112)  
 
Recent studies suggest that adenocarcinoma is more common than previously 
reported.(75) A North American series describes a recent change of the most 
common lung cancer from SCC to adenocarcinoma.(75) However, these studies 
included more females with lung cancer than males.(75) Other areas namely; 
Egypt, Jordan, Palestine, Saudi Arabia and United Arab Emirates also describe 
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higher adenocarcinoma to SCC ratios in females.(112) This may be due to 
hormonal factors or change in smoking trends. In the Cape Town study, a gender 
difference was not described,(20) but in the Bloemfontein and Johannesburg 
study, adenocarcinoma was more common in males compared to females.(18, 19) 
Similarly, in our study, adenocarcinoma was only diagnosed in males, perhaps 
reflecting similar smoking trends or social habits to Bloemfontein and 
Johannesburg. The unequal distribution of males and females in this study may 
account for SCC being the predominant lung cancer type. 
  
The majority of the SCC patients in our study were African males. When compared 
to the Bloemfontein study, SCC was almost equally distributed between African 
and White racial groups with the coloured population having the least SCC 
diagnoses.(18) Conversely, SCC was most frequent in the White population in the 
Johannesburg cohort.(19) Variation regarding types of lung cancer in South Africa 
appears to differ geographically rather than racially.   
 
Cigarette smoking is a well described risk factor for SCC.(55, 56) A study 
conducted in Spain links an 80 pack year smoking history exclusively with 
SCC(56). Unfortunately, specific smoking pack year history was poorly 
documented in the chart notes in this retrospective study. Nevertheless, smoking 
is likely to be the main risk factor for SCC in patients in our setting too.  
 
6.6. Outcomes of Bronchoscopy 
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Bronchoscopy assisted with the diagnosis of broncho-respiratory pathology for 
35.5% of the sample group. Studies in Saudi Arabia and Egypt demonstrated 
higher overall diagnostic yields of 58% and 67% respectively.(17, 30) In these 
studies, the majority of bronchoscopy diagnoses were in patients referred for 
suspected lung cancer or TB.(17, 30) In our study, the highest diagnostic rates 
was in patients referred for investigation of diffuse pulmonary infiltrates and 
suspected lung mass with 46.7% and 46.5% achieving a microbiological and 
histological diagnosis respectively. Although suspected TB was the second most 
requested indication for bronchoscopy, it was not a common finding on samples 
obtained by bronchoscopy.  
 
As South Africa has the leading HIV associated incident TB cases globally and 
smear negative TB is more common in HIV infected patients, a high index of 
suspicion for the diagnosis of TB should be maintained.(33) Patients with true 
smear negative TB, maybe hypoxic and unable to tolerate a bronchoscopy,  which 
may have contributed to an underestimation of TB, using BAL in the diagnosis of 
TB in our study.  
 
In our study, biopsy confirmed lung cancer in 46.5% of all bronchoscopies 
performed for suspected malignancy. This result demonstrates a low yield 
compared to other studies. Detection rates of lung cancer on biopsy during 
bronchoscopy vary from 57% to 94% in different studies.(16, 30, 88-90) This was 
calculated as the percentage of lung cancer detected on biopsy during 
bronchoscopy amongst those patients referred with suspected malignancy.   
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6.7. Complications of Bronchoscopy 
The documented complication rates of bronchoscopy vary from 0.5% to 11%.(28, 
29, 113-115) In a large multicentre study of 20 986 bronchoscopies in Italy, the 
complication rate was 1.08% and the largest number of complications were 
associated with trans-bronchial needle biopsy.(29) The common complications 
were haemoptysis (0.45%), hypoxaemia (0.12%) and pneumothorax (0.1%).(29) In 
this study, 3.7% of patients experienced a complication during or after 
bronchoscopy. These complications were hypoxaemia and haemoptysis and were 
recognised complications in other studies.(28, 29, 114, 115) 
 
The frequency of complications of our study was within the described and 
expected range. In the study by Dreiser et al, which noted a higher complication 
rate of 11%, bronchoscopy procedures were performed mainly by pulmonary 
fellows in training reflecting less developed technical skills and was associated 
with trans-bronchial needle biopsies mainly.(113) Due to the prospective study 
design it was more likely to detect even minor complications that may have been 
overlooked in retrospective studies.(113) In our study, however, all 
bronchoscopies were performed by a trained expert and the design was 
retrospective in nature. Furthermore, no trans-thoracic needle biopsies were 
undertaken. It is unclear whether the smaller sample size attributed to the 
relatively higher frequency of complications. 
 
6.8. Study Limitations 
102 
 
There are several limitations that were identified in our study. The study was 
conducted at a tertiary referral hospital and hence referral bias limits the 
generalisation of the findings. In addition, patients who undergo bronchoscopy 
need to be medically “fit” to tolerate the bronchoscopy as hypoxia is a pre-
procedure exclusion criterion. Patients who are very ill with respiratory illness and 
are unstable for transfer to the tertiary level may also not be eligible for 
bronchoscopy. These factors may have contributed to selection bias.  
 
Due to the retrospective study design, information was limited to what was already 
noted in clinical records. Missing and incomplete records resulted in missing data. 
This further contributed to bias. 
 
The sample size was limited by the number of bronchoscopies done in the year. 
Although data was collected for a year, not every patient with suspected smear 
negative TB, suspected malignancy and/ or other respiratory pathologies where no 











The value of the bronchoscopy in the diagnosis of lower respiratory tract infections 
(LRTI) and lung cancer is well established. Studies describing the indications and 
outcomes of bronchoscopy are mainly from the Middle East, United Kingdom and 
United States of America and there is a lack of information from South Africa and 
other resource limited settings.  
 
Bronchoscopy assisted with microbiological, cytological or histological diagnosis of 
broncho-respiratory pathology in over one third of patients in this study. Although 
the commonest indication for bronchoscopy was the investigation of a lung mass, 
a diagnosis was more commonly established in those referred for investigation of 
diffuse pulmonary infiltrates. Bronchoscopy confirmed a microbiological diagnosis 
of LRTI in just under half of all patients referred for investigation of diffuse 
pulmonary infiltrates. This is an important finding in South Africa because 
pneumonia and tuberculosis (TB) are the leading causes of mortality.(2) Samples 
collected during bronchoscopy aid in microbiological diagnoses which leads to 
prompt and directed antibiotic treatment. This may assist in reducing mortality from 
pneumonia, however, further studies assessing the value of bronchoscopy in the 




KwaZulu Natal has the highest prevalence of drug resistant TB in South Africa.(33) 
TB is the main cause of mortality in this region.(2) In this study, the prevalence of 
TB on smear negative patients was 11.1% of those referred with suspected TB. 
This finding was lower than that described in other studies. There are, however, 
few studies of this nature in South Africa. The low TB detection rate in this study 
was attributed to referral and survival bias as the study was conducted at a tertiary 
hospital. Bronchoscopy as a means to detect TB appears to be largely under-
utilised in this setting.  
 
According to the national cancer registry of 2006, lung cancer was the fourth most 
common type of cancer in males.(12) Due to a lack of an updated cancer registry 
since 2006 the true burden of cancer in South Africa is unknown. Information 
regarding lung cancer in South Africa has therefore only been available through 
limited studies. In this study bronchoscopy confirmed a histological diagnosis of 
lung cancer in over one third of patients referred with a suspected lung mass.  
 
Different subtypes of lung cancer appear to be endemic to different areas in South 
Africa. In Cape Town, adenocarcinoma is the most frequent lung cancer,(20) 
whilst in Bloemfontein and Johannesburg squamous cell carcinoma (SCC) is more 
common.(18, 19) In this study, SCC was the most frequently diagnosed lung 
cancer. The reasons for the geographical difference in histological subtypes of 
lung cancer are unknown and may be attributed to smoking trends and different 




There are several limitations that were identified in this study. Referral and survival 
bias were therefore major limitations in the study as Greys Hospital is a tertiary 
hospital that requires patients to be referred by surrounding district hospitals 
before they receive special investigation and/ or treatment.  
 
Due to the retrospective study design and lack of standardised clinical case record 
information, availability of data was limited to clinical and laboratory records only. 
Missing and incomplete records further contributed to the bias of the findings. This 
limits the generalisation of the findings in this study. 
 












OPERATIONAL RECOMMENDATIONS AND FUTURE DIRECTIONS 
 
8.1. Respiratory tract infection is the leading cause of natural deaths in South 
Africa.(2) This study demonstrates that bronchoscopy was useful in assisting with 
microbiological diagnosis of pneumonia in patients with diffuse pulmonary 
infiltrates and non-resolving lower respiratory tract infections (LRTI). Prompt 
referral of patients with diffuse pulmonary infiltrates and non-resolving LRTI is 
recommended to prevent the morbidity and mortality associated with pneumonia. 
 
8.2. Bronchoscopy is a limited resource in KwaZulu Natal. It is performed by 
specialist pulmonologists and therefore the services are currently only available at 
two public sector hospitals in KwaZulu Natal. Bronchoscopy, nevertheless, 
remains a valuable resource in the diagnosis of smear negative tuberculosis (TB). 
The prevalence of TB on broncho-alveolar lavage (BAL) in smear negative cases 
was 11.1% which is lower than other centres. The use of BAL for the diagnosis of 
TB is largely an underutilised resource in Greys Hospital. Timeous referral of 
smear negative TB suspects is recommended to establish a diagnosis and 
ameliorate the mortality associated with TB.  
 
8.3. This study was conducted during transition from using sputum acid fast bacilli 
(AFB) to GeneXpert® for the diagnosis of TB in South Africa. GeneXpert® was 
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available toward the end of 2011. GeneXpert® in the diagnosis of TB is now 
commonly utilised in South Africa. Although it can be used on gastric lavage 
samples, GeneXpert® on BAL samples is not yet advised by the Department of 
Health. (Appendix 1) More studies are required to establish the operational 
efficacy of GeneXpert® on BAL samples in the diagnosis of TB. 
 
8.4. In this study, squamous cell carcinoma (SCC) was the most common lung 
cancer diagnosed. There appears to be a geographic variation of histological 
subtypes of lung cancer across South Africa, however, the reasons for this are still 
to be established. A multicentre, prospective study of risk factors and incidence of 
lung cancer is recommended to determine the risk factors and burden of disease 
for the different subtypes of lung cancer. 
 
8.5. Human immunodeficiency virus (HIV) and TB have an unclear causal 
relationship with lung cancer. Due to the high co-infection rates of TB/HIV in South 
Africa this is an ideal site to explore this association. 
 
8.6. In this study chest computed tomography (CT) scan was compared to 
bronchoscopy in the detection of lung cancer. Chest CT scan had a high negative 
predictive value suggesting that it was a useful rule out test. Chest CT scan is 
therefore recommended prior to bronchoscopy in all patients in whom lung cancer 




8.7. Lack of standardised reports of patients undergoing bronchoscopy resulted in 
missing information and results of investigations. It is recommended that all 
patients be reviewed by the pulmonology team prior to and post bronchoscopy to 
ensure that all sputum, bronchoscopy and radiology results are indexed in a 
standardised format and followed up.    
 
8.8. This bronchoscopy unit lacks more updated bronchoscopy equipment. The 
unit is unable to perform endobronchial ultrasounds, auto-fluorescent 
bronchoscopy, electromagnetic bronchoscopy and navigational bronchoscopy. 
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CASE REPORT FORM 
 
IDENTIFICATION 
Identification study number: _ _ _ _ _ _ 
 
DEMOGRAPHICS 
Date of birth     _ _ _ _/ _ _/ _ _ 
Age: 
Gender:      Female                  Male    
Race:  African    White     Coloured    Asian    Other   
 
REFERRAL 
Was the patient referred to Greys Hospital?  Yes    No   
 If yes, name of the referral hospital/clinic/GP? _ _ _ _ _ _ _ _ _ _ 
What is the final outcome of the patient?   





What is the patient‟s haemoglobin? _ _ _ _ _g/dl 
What is the patient‟s INR? _ _ _ _ _ 
What is the oxygen saturation of the patient? _ _ _ _ _% 
 
INDICATIONS 
What was the indication for the bronchoscopy? 
Haemoptysis    Lung Mass    Non resolving LRTI     Suspected 
TB     Diffuse pulmonary infiltrates    Other    Specify _ _ _ _ _ 
_  
What is the patients HIV status?  Positive    Negative    Unknown   
 If positive what is the corresponding CD4 count? _ _ _ _  
 Is the patient on antiretrovirals?  Yes       No  
 If yes what medications? 3TC    TDF    EFV   
           D4T    AZT    NVP   
           ABC    Ritonavir/loponivir    other: _ _ _ _ _ _ _                
Does the patient smoke?  Yes     No   
 If yes, how many pack years? _ _ _ _ _ _ _  
 If no, has the patient ever smoked previously?  Yes     No   
127 
 
Family history of malignancy?   Yes     No   
 Primary lung malignancy        other     _ _ _ _ _ _ _ 
Occupational history? 
 Exposure to lung irritants?  Yes     No   
 What irritant? _ _ _ _ _ _ _ _ _ _ _ _ 
 Protective equipment used?    Yes     No   
Was sputum collected? Yes    No   
 MC+S result? _ _ _ _ _ _ _  
 Ziel Neelson AFB result?  Positive     Negative   
culture result? _ _ _ _ _ 
sensitivity result? _ _ _ _ _ 
 cytology result?  Malignant cells     No malignant cells   other _ _ _  
 
RADIOLOGY 
Was a chest radiograph done?  Yes    No   
 If yes does it report a: mass    infiltration    infection   other 
specify _ _ _  
Was a CT Chest done?  Yes    No   
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 If yes does it report a: mass    infiltration    infection   other 
specify _ _ _  
 
DESCRIPTION AND SAMPLING AT BRONCHOSCOPY 
Endobronchial biopsy        Yes         No  
Transbronchial biopsy       Yes         No   
BAL: MCS      AFB      TB Culture      Fungal      PCP    
Cytology   
Was a mass visualised? Yes     No   
Description of mass _ _ _ _ _ _ _ 
 
RESULTS 
Was the result of the sample available?  Yes       No    
 If yes specify_ _ _ _ _ _ _ _ _ _ _ _ _ 
 Histology result_ _ _ _ _ _ _ _ _ _  
 If no could it be traced?  Yes      No   
Was the specimen sufficient? Yes     No   
Did the sample leak? Yes      No   




Where there any procedure related complications?  Yes   No   
If yes specify: Haemoptysis     Pneumothorax    Bronchospasm                                                                   
































LIST OF ABBREVIATIONS 
 
ACCP - American College of Chest Physicians 
AFB - Acid fast bacilli 
ART - Antiretroviral therapy 
BAL - Broncho-alveolar lavage 
Cells/mm3 - Cells per cubic millimetre 
CD4 - Cluster of differentiation 4 
cfu - Colony forming units 
CI - Confidence interval 
cm - Centimetres 
COPD - Chronic obstructive pulmonary disease 
CT - Computed tomography  
DNA - Deoxyribonucleic acid 
DST - Drug susceptibility testing 
e.g. - as an example 
EGFR - Epidermal growth factor receptor 
ERBB2 - v-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 2 
g/dl - Grams per decilitre 
Hb - Haemoglobin 
HIV - Human immunodeficiency virus 
INR - International normalised ratio 
IQR – Interquartile range 
KRAS - Kirsten rat sarcoma viral oncogene homolog  
KZN - KwaZulu Natal 
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LPA - Line probe assay 
LRTI - Lower respiratory tract infection 
MC&S - Microscopy, culture and sensitivity  
MDR TB - Multidrug resistant tuberculosis  
mg/kg - Milligrams per kilogram 
ml - Millilitres 
MTB/RIF - Mycobacterium tuberculosis/ rifampicin 
NHLS - National health laboratory service 
NICE - National institute for health and clinical excellence 
NNRTI - Non-nucleoside reverse transcriptase inhibitor 
NRTI - Nucleoside reverse transcriptase inhibitor 
PACS - Picture archiving and communication centre 
PCP - Pneumocystis jirovecii pneumonia 
PCR - Polymerase chain reaction 
PI - Protease inhibitor 
SCC - Squamous cell carcinoma 
SD - Standard deviation 
Spp - Species 
TB - Tuberculosis 
XDR TB - Extreme drug resistant tuberculosis 
ZN - Ziehl Neelsen 
